

The Efficacy and Safety of Early Renal Replacement Therapy in Critically III Patients With Acute Kidney Injury: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials

Chuan Xiao^{1,2†}, Jingjing Xiao^{2†}, Yumei Cheng^{1,2}, Qing Li^{1,2}, Wei Li^{1,2}, Tianhui He^{1,2}, Shuwen Li^{1,2}, Daixiu Gao^{1,2} and Feng Shen^{1,2*}

¹ Department of Intensive Care Unit, The Affiliated Hospital of Guizhou Medical University, Guiyang, China, ² School of Clinical Medicine, Guizhou Medical University, Guiyang, China

OPEN ACCESS

Edited by:

Nattachai Srisawat, Chulalongkorn University, Thailand

rontiers

in Medicine

Reviewed by:

Wisit Kaewput, Phramongkutklao Hospital, Thailand Konlawij Trongtrakul, Chiang Mai University, Thailand

*Correspondence:

Feng Shen doctorshenfeng@163.com

[†]These authors have contributed equally to this work and share first authorship

Specialty section:

This article was submitted to Intensive Care Medicine and Anesthesiology, a section of the journal Frontiers in Medicine

Received: 23 November 2021 Accepted: 11 January 2022 Published: 21 February 2022

Citation:

Xiao C, Xiao J, Cheng Y, Li Q, Li W, He T, Li S, Gao D and Shen F (2022) The Efficacy and Safety of Early Renal Replacement Therapy in Critically III Patients With Acute Kidney Injury: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials. Front. Med. 9:820624. doi: 10.3389/fmed.2022.820624 The efficacy and safety of early renal replacement therapy (eRRT) for critically ill patients with acute kidney injury (AKI) remain controversial. Therefore, the purpose of our study was to perform an up-to-date meta-analysis with the trial sequential analysis (TSA) of randomized controlled trials (RCTs) to evaluate the therapeutic effect of eRRT on patients in an intensive care unit (ICU). We extensively searched MEDLINE, EMBASE, LILACS, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov, Gray Literature Report, and Bielefeld Academic Search Engine (BASE), and conducted an updated search on December 27, 2021. The included studies were RCTs, which compared the efficacy and safety of eRRT and delayed renal replacement therapy (dRRT) on critically ill patients with AKI. We adopted TSA and sensitivity analysis to strengthen the robustness of the results. About 12 RCTs with a total of 5,423 participants were included. Patients receiving eRRT and dRRT had the similar rate of all-cause mortality at day 28 (38.7% vs. 38.9%) [risk ratio (RR), 1.00; 95%Cl, 0.93–1.07, p = 0.93, $l^2 = 0\%$, p = 0.93]. A sensitivity and subgroup analysis produced similar results for the primary outcome. TSA showed that the required information size was 5,034, and the cumulative Z-curve crossed trial sequential monitoring boundaries for futility. Patients receiving eRRT had a higher rate of renal replacement therapy (RRT) (RR, 1.50, 95% CI: 1.28–1.76, p < 0.00001, $l^2 =$ 96%), and experienced more adverse events comparing to those receiving dRRT (RR: 1.41, 95% CI: 1.22–1.63, p < 0.0001, heterogeneity not applied). The most remarkable and important experimental finding is that, to our knowledge, the current meta-analysis included the largest sample size from the RCTs, which were published in the past 10 years to date, show that eRRT had no significant survival benefit for ill patients with AKI compared with dRRT and TSA indicating that no more studies were needed to confirm it.

Trial Registration: INPLASY, INPLASY2020120030. Registered 04 December 2020.

Keywords: mortality, early renal replacement therapy, delayed renal replacement therapy, acute kidney injury, trial sequential analysis (TSA)

INTRODUCTION

Acute kidney injury (AKI) is an important complication in patients who are admitted to an intensive care unit (ICU) and is associated with a high risk of death (1). AKI could result from prerenal azotemia, acute tubular necrosis, or post-renal obstructive disease (2). Renal replacement therapy (RRT) is an effective treatment for AKI when indicated (3), helping to optimize fluid administration and hemodynamic management, etc. (4–6). Therefore, RRT is often applied whenever patients suffered from fluid overload and/or other complications [7–9] (7, 8).

However, there is no optimal timing of RRT, and whether early RRT (eRRT) is superior to delayed RRT (dRRT) is also a matter of controversy (9–11). Some multicenter, randomized controlled trials (RCTs) indicated that eRRT has not shown clinical benefits (12, 13), but others demonstrated that eRRT significantly reduces the mortality of patients with AKI (6, 14).

In view of controversial results, recently, two high-quality RCTs were published in NEJM (15) and Lancet (16), which compared the effects of eRRT vs. dRRT on critically ill patients with AKI. So, we did an updated systematic review involving sufficient patients from RCTs to explore the uncertainty arising from conflicting results. Review evidence may provide contemporary evidence to guide clinical policies and practices.

In the traditional meta-analysis, the positive results are easy to be changed after more evidence is accumulated (17). The trial sequential analysis (TSA), however, has the potential to make conclusions more reliable than traditional meta-analyses (18, 19). TSA can also provide "futility boundaries" to identify invalid conclusions earlier, preventing researchers from spending a lot of resources on unneeded research. Here, we performed TSA to minimize random errors in a cumulative meta-analysis and strengthen the robustness of the results.

METHODS

Overview

Our systematic review was registered at INPLASY (INPLASY2020120030), (https://inplasy.com/inplasy-2020-12-0030/), following a prespecified protocol and complying with the Preferred Reporting Items for Systematic Meta-Analyses (PRISMA) guideline (20).

Eligibility Criteria

We included studies, which met all the following criteria: (1) RCTs published from January 1, 2010, to October 11, 2020, and an updated search was conducted on December 27, 2021. (2) Subjects were critically ill patients (\geq 18 years) with AKI (KDIGO

stage 2 or 3, or at the failure stage of RIFLE) (21). (3) With a clear criterion used for defining eRRT and dRRT.

Search Strategy

We did an extensive electronic search from January 1, 2010, to October 11, 2020, based on the recommendations (20, 22) from MEDLINE, EMBASE, LILACS, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov, and conducted an updated search on December 27, 2021. Besides, we searched the two gray literature databases: The Grey Literature Report (www.greylit.org/) and Bielefeld Academic Search Engine (BASE) (http://www.base-search.net/about/en/). The detailed retrieval method was included as **Supplementary Materials**.

Selection of Studies

The two authors independently screened research titles and abstracts that were potentially relevant to this article according to the inclusion criteria. To determine studies that meet the inclusion criteria of this study, we retain potentially relevant data and research information and evaluate the full text when necessary. Any disagreements in the selection of studies were negotiated or consulted with a third review author if necessary.

Data Extraction and Effect Measure

Data were independently entered into an Excel spreadsheet by three reviewers. We collected the data including first author, recruitment period, the year of publication, sample size, mean age, gender, RRT modality, primary outcome: all-cause mortality at day 28, secondary outcomes: all-cause mortality at days 60 and 90, all-cause mortality in an ICU and a hospital, the length of stay (LOS)in an ICU and a hospital, ventilator-free days vasoactive agents free days/rate of RRT dependence at day 28, and the risk of total adverse events and specific adverse events (bleeding, arrhythmia, and hypotension). Any disagreements in data extraction were negotiated or consulted with a third review author if necessary. For binary classification results, the risk ratio (RR) with 95% CI was used to describe the binary classification results, and the mean difference (MD) with 95% CI was used to describe continuous variables.

Risk of Bias Assessment and Certainly Assessment

At least two review authors independently evaluated the methodological quality of each included trial and assessed the risk of bias according to the Cochrane Handbook for Systematic Reviews of Interventions (22). Included trials were judged for the risk of bias in all bias domains (23). Any disagreements concerning the assessment of the risk of bias were negotiated with a third review author if necessary. We assessed the certainty of the evidence for all-cause mortality at day 28, the LOS of survivors in an ICU and a hospital, the rate of RRT dependence at day 28, and the incidence of total adverse events by grading with Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) pro GDT (24) available from gdt.gradepro.org.

Abbreviations: eRRT, early renal replacement therapy; AKI, acute kidney injury; TSA, trial sequential analysis; RCTs, randomized controlled trials; dRRT, delayed renal replacement therapy; RR, risk ratio; CI, confidence interval; GRADE, Grading of Recommendations, Assessment, Development and Evaluations; ICU, intensive care unit; RRT, renal replacement therapy; LOS, the length of stay; RRR, relative risk reduction; SOFA, Sequential Organ Failure Assessment; APACHE II, Acute Physiology and Chronic Health Evaluation; FST, furosemide stress test; pNGAL, plasma neutrophil gelatinase associated lipocalin.



Reporting Biases Assessment

Visual inspection of funnel plots and contour-enhanced funnel in the graphic was used to assess the potential existence of reporting bias. Besides, Begg's and Egger's tests were performed to quantitatively assess the publication bias.

Data Analysis

We undertook this systematic review following the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions (22) and Meta package for the R language. We performed a meta-analysis for the outcomes with comparable methods in a similar population when more than one trial was included by using statistical software Review Manager 5. We set p < 0.05 as the statistical significance and represented individual trial and summary reports with 95% CIs. Moreover, we evaluated the statistical heterogeneity of each outcome through the I^2 statistic measure and chi-squared test, in which p < 0.1 was regarded as to be significant. We adopted a random-effects model in all analyses because of fears of that clinical heterogeneity and methodological heterogeneity. To explore the eventual sources of heterogeneity, we conducted the respective subgroup analyses based on these characteristics including study design, patient population, the modality of RRT, and the presence of sepsis at randomization for the primary outcome. We also performed sensitivity analyses for the primary outcome such that investigating the potential effect of excluding studies judged as being at unclear or a high risk of bias in any of the risk of bias domains. Furthermore, we implemented the two important analyses, the "best-worst-case" scenario and the "worst-best-case" scenario (25) to assess the possible impact of missing data on the primary outcome.

Trial Sequential Analyses

Recent studies showed that TSA has the potential to make conclusions more reliable than those traditional meta-analyses (18, 26). Also in traditional meta-analyses, it is sometimes to get positive conclusions resulting from "random error" rather than a "real" intervention effect (27). In this situation, the TSA software provides methods to minimize the incidences of these false positive results (28). TSA is also able to provide "futility boundaries" that could draw invalid conclusions early (27, 29). In our analysis, we conducted TSA using the TSA software (version 0.9.5.10 Beta) (19), of which the information size was calculated according to an anticipated—relative risk reduction (RRR) of 15% with a power of 90% (15, 30) and a type-I error value of 1% (two-sided).

RESULTS

Research Results

We totally screened 2,108 titles and abstracts of which 504 fulltext reports were assessed for eligibility and 492 references were excluded due to some reasons (**Figure 1**). About 12 records were finally included for a meta-analysis and 9 of them were selected in quantitative synthesis for the primary outcome in our meta-analysis (**Figure 1**).

Characteristics of the Studies

About 12 RCTs fulfilled the planned inclusion criteria. The baseline characteristics of the included studies are presented in **Table 1**. Around 9 of 12 studies came from a multi-center (12, 13, 15, 16, 30–34), while the other 3 came from a single-center (6, 35, 36). Severity scores of diseases reported mostly were Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation (APACHE II).

The criteria for eRRT and dRRT of the included trials are depicted in Table 2. In the RENAL study by Jun et al. (31), as 439 patients were assigned to four groups according to variant initiating time of CRRT other than to early and delay initiation, we only selected the patients from the earliest (within 7.1 h of AKI diagnosis) and latest group (46 h after AKI diagnosis). Therefore, only 220 of 439 patients were included for analysis. In a trial by Lumlertgul et al. (13), the furosemide stress test (FST) was performed for all patients with AKI, FST-nonresponsive patients were then randomized to eRRT or dRRT, and 118 of 162 patients were included for analysis. In the trials by Srisawat et al. (34) and Xia et al. (36), patients were grouped based on the level of plasma neutrophil gelatinase-associated lipocalin (pNGAL), and only patients with a high level of pNGAL were assigned to receive either eRRT or dRRT, resulting in the inclusion of 40 of 60 patients from Srisawat's trial and of 60 of 100 patients from Xia's trial in our analysis.

About 12 RCTs with a total of 5,423 patients were included in a meta-analysis, of whom 2,728 received eRRT and other 2,695 received dRRT. The basic characteristics of 5,423 patients were detailed in **Table 3**. These patients had similar age, sex ratio, serum creatinine, blood urea nitrogen, and SOFA score in eRRT and dRRT groups.

Quality of Studies

We evaluated the risk of bias for each included article following the Cochrane ROB (risk of bias) tool (**Figure 2A**) and graphed the degrees of risk of bias (**Figure 2B**). Of the included studies, 8 (67%) studies were judged to have a low risk of bias, and 3 (25%) were judged to have a high risk of bias, while 1 study (8%) was unclear.

Certainty of the Evidence

Six main outcomes were graded by the GRADE for the quality of evidence (**Table 4**). The results of the analysis showed that the certainty of the evidence was high for the mortality at day 28, the rate of RRT, moderate for the LOS of survivors in an ICU, the LOS survivors in a hospital, and total adverse events. Meanwhile, the evidence for RRT dependence at day 28 was of low certainty due to serious inconsistency and imprecision.

Quantitative Data Synthesis Primary Outcomes

About 9 of 12 trials with a total of 4,981 participants and a mean follow-up of 28 days reported all-cause mortality (6, 12, 13, 15, 16, 30, 34, 36). About 442 of 5,423 (8.1%) patients did not have complete data on the prespecified primary outcome. For the remaining 4,981 patients, the rates of all-cause mortality at day 28 (38.7% in eRRT and 38.9% in dRRT) were not significantly

Author Year		Country	Country	Country	Country	Design setting and Population	sign Median time of ng and RRT initiation ulation (IQR), h		No. of pation	ents	Female	e (%)	Mean po age, yea	pulation ars (SD)	SOFA	A(SD)	APACHEII (SD)		RRT modality	Missing primary outcome
				eRRT	dRRT	eRRT	dRRT	eRRT	eRRT	eRRT	dRRT	eRRT	dRRT	eRRT	dRRT					
Sean M	2020	Nationwide	e Multicenter mixed population	6.1 (3.9,8.8)	31.1 (19.0,71.8)	1465	1462	470/1465 (31)	467/1462 (32)	65(14)	65(13)	12(4)	12(4)	NA	NA	CRRT	No			
Gaudry	2021	France	Multicenter mixed population	33 (24,60)	3 (2,5)	137	141	35 (26)	38 (27)	65 (13)	65(12)	NA	NA	NA	NA	IHD, CRRT Mixed	No			
Gaudry	2016	France	Multicenter mixed population	2 (1, 3)	57 (25,83)	311	308	102/311 (32.7)	110/308 (35.7)	65(14)	67(13)	NA	NA	NA	NA	IHD, CRRT	No			
Barbar	2018	France	Multicenter mixed population	7.6 (4.4,11.5)	51.5 (34.6,59.5)	246	242	104/246 (42.2)	88/242 (36.3)	69(12)	69(13)	NA	NA	NA	NA	CRRT IHD Mixed	No			
Lumlertgi	ul 2018	Thailand	Multicenter mixed population	2 (1, 3)	21 (17,49)	58	60	29/58 (50)	31/60 (52)	68(15)	67(17)	13(3)	11(4)	24.5(6.4)	21.8(6.9)	CRRT	No			
Zarbock	2016	Germany	Single-center Surgical population	6 (4, 7)	25.5(18.8)40.3)	112	119	34/112 (30.3)	51/119 (42.9)	66(14)	68(13)	16(2)	16(2)	30.6(7.5)	32.7(8.8)	CRRT IHD MIXED	No			
XIA	2019	China	Single-center mixed population	NA	NA	30	30	15/30 (50)	12/30 (30)	65(12)	67(11)	10(3)	10(3)	19.25(3.4	3)18.34(3.2	7)CRRT	No			
Srisawat	2017	Thailand	Multicenter. mixed population	NA	NA	20	20	NA	NA	NA	NA	NA	NA	NA	NA	CRRT	No			
Tukaram E	2013	India	Single-center medical population	NA	NA	102	106	40/102 (39.2)	27/106 (25.5)	43(15)	42(16)	8(3)	8(3)	NA	NA	IHD	Yes			
Vaara	2014	Finnish	Multicenter mixed population	3.3(2.0–7.4)	35.5(22.7– 59.8)	90	44	31/90 (34.4)	23/44 (52.3)	64(11)	67(16)	12(4)	12(4)	NA	NA	CRRT	Yes			
Wald	2015	Canada	Multicenter mixed population	7.4 (6.1,9.6)	31.6 (22.8,59.5)	48	52	13/48 (27.1)	15/52 (28.8)	62(12)	64(14)	13(3)	13(3)	NA	NA	IHD, SLED, CRRT	Yes			
jun	2014	Australia New Zealand.	Multicenter mixed population	NA	NA	109	111	36/109 (33)	36/111 (32)	66(13)	64(15)	2(1)	2(2)	NA	NA	CRRT	No			

TABLE 1 | Baseline characteristics of the randomized controlled clinical trials included in the meta-analysis.

APACHE II, Acute Physiology and Chronic Health Evaluation II; SOFA, Sequential Organ Failure Assessment; CRRT, continuous renal replacement therapy; IHD, Intermittent hemodialysis; SLED, Sustained low-efficiency dialysis; HCO-CVVHD, high cut-off continuous veno-venous hemodialysis; NA, not available.

TABLE 2	Definitions of early	v and delaved renal	replacement therapy	(RRT) in	individual studies
	Dominions of our		replacement therapy	(1 11 1 1 / 11	

Author	Year Early initiation Criteria		Delayed initiation Criteria
Gaudry (AKIK2)	2021	Within 12 h after fulfilling the randomization criteria.	Severe hyperkalemia (>6 mmol/l); hyperkalemia (>5.5 mmol/l) persisting despite medical treatment; Severe metabolic acidosis (pH <7.15); Severe pulmonary oedema; serum urea >40 mmol/L for 1 day.
Sean (STARRT-AKI)	2020	Within 12 h after fulfilling the randomization criteria.	Severe hyperkalemia (>6 mmol/l); Severe metabolic acidosis (pH <7·2); severe pulmonary oedema; persistent AKI for at least 72 h after randomization.
Gaudry (AKIK)	2016	Within 6 h after documentation of AKI stage 3 of KDIGO classification	Severe hyperkalemia (>6 mmol/L); severe pulmonary, oedema refractory to diuretics; severe acidosis (pH <7·15); serum urea >40 mmol/L; oligo-anuria >72 h
Barbar (IDEAL-ICU)	2018	Within 12 h after the onset of acute kidney injury that was determined to be at the failure stage of the risk, injury, failure, loss, and end-stage kidney disease (RIFLE) classification	Severe hyperkalemia (>6.5 mmol/L); severe pulmonary oedema refractory to diuretics; severe metabolic acidosis (pH <7.15); no renal function recovery after 48h
Lumlertgul (FST)	2018	Within 6 h of randomization	Serum urea ≥100 mg/dL; Severe hyperkalemia (>6 mmol/L); Severe metabolic acidosis (pH <7·15); Severe pulmonary oedema
Zarbock (ELAIN)	2016	Within 8 h of stage 2 AKI diagnosed	Within 12 h of stage 3 AKI indicated
XIA	2019	Performed as soon as possible	Severe hyperkalemia (>6.5 mmol/L); Severe pulmonary oedema; Severe metabolic acidosis (pH <7.20)
Srisawat	2017	A session of CRRT was run within 12 h after group assignment for early RRT group	Severe acidosis (Ph<7.2), severe peripheral edema, pulmonary edema, no response to diuretics, refractory hyperkalemia (>6.5 mmol/L or the presence of ECG change: tall T wave, absent P wave, or wide QRS wave), anuria or oliguria, or high BUN level>60 mg/dL.
Tukaram E	2013	Serum urea nitrogen level increased to 70 mg/dL and/or creatinine level increased to 7 mg/dL irrespective of complications	Treatment-refractory hyperkalemia, volume overload, and acidosis. Uremic nausea and anorexia leading to inability to maintain nutrient intake also were indications to initiate dialysis therapy
Vaara	2014	Within 12 h from manifestation of indications	RRT initiated 12 h after indications: hypercalcemia, severe acidosis, plasma urea.36 mmol/L, oliguria, or anuria, fluid overload with pulmonary edema
Wald	2015	Within 12 h from eligibility	Severe hyperkalemia (>6 mmol/L); severe pulmonary oedema; severe metabolic acidosis (serum bicarbonate <10 mmol/L)
Jun (RENAL)	2014	Within 7.1h of AKI diagnosed according to RIFLE criteria	After 46h of AKI diagnosed according to RIFLE criteria

KDIGO²², kidney disease: improving global outcomes; RIFLE⁴⁴, risk, injury, failure, loss, and end-stage kidney disease.

KDIGO 1: 1.5–1.9 times baseline or UOP 26.5 umol/L (0.3 mg/dl) increase in creatinine within 48 or UOP <0.5 ml/kg/h for 6–12 h.

KDIGO 2:2.0–2.9 times baseline increases in creatinine or UOP <0.5 ml/kg/h for > 12 h.

KDIGO 3: 3.0 times baseline or creatinine \geq 354 umol/L (4.0 mg/dl) or UPO <0.3 ml/kg/h for > 24 h or anuria for \geq 12 h. AKI, Acute renal injury.

TABLE 3 | Characteristics of patients from the randomized controlled trials (RCTs) included in the meta-analysis.

	eRRT group	dRRT group	95% CI*	Р
Age	64.3 ± 14.6	64.7 ± 14.4	-0.04(-0.10,0.02)	0.23
Female (%)	918(33.6%)	898 (33.5%)	1.00(0.90,1.12)	0.97
SOFA score	11.2 ± 4.1	11.3 ± 4.1	-0.01(-0.28,0.29)	0.24
Serum creatinine(mg/dl)	3.7 ± 2.3	3.6 ± 2.2	-0.24(-0.49,0.08)	0.25
Blood urea nitrogen (mg/dL)	58.6 ± 32.2	62.1 ± 32.0	-5.45(-14.39,3.49)	0.23

Data are presented as means \pm SD or n/N (%).

SOFA, Sequential Organ Failure Assessment.

*For binary classification results, the risk ratio (RR) with 95% Cl was used to describe the binary classification results, and the mean difference (MD) with 95% Cl was used to describe continuous variables.



TABLE 4 | Summary of findings.

Early RRT compared to Delayed RRT for critically ill patients with acute kidney injury Patient or population: critically ill patients with acute kidney injury Setting: Critical care Intervention: Early RRT

Outcomes	Anticipated absolu (95% Cl)	te effects*	Relative effect	No of participants	Certainty of the evidence	Comments
	Risk with Delayed RRT	Risk with Early RRT	(95% CI)	(studies)	(GRADE)	
28 -day mortality	389 per 1,000	389 per 1,000 (362 to 417)	RR 1.00 (0.93 to 1.07)	4981 (9 RCTs)	$\oplus \oplus \oplus \oplus HIGH$	
the rate of RRT	633 per 1,000	950 per 1,000 (810–1,000)	RR 1.50 (1.28–1.76)	5069 (10 RCTs)	$\oplus \oplus \oplus \oplus HIGH$	
The rate of RRT-dependence at day 28	154 per 1,000	123 per 1,000 (77–198)	RR 0.80 (0.50–1.29)	1229 (7 RCTs)	$\oplus \oplus \bigcirc \bigcirc$ LOW	
LOS of hospital in survivors	-	MD 2.74 lower (4.93 lower–0.55 lower)	-	4365 (5 RCTs)	⊕⊕⊕○ MODERATE	
LOS of Icu in survivors	-	MD 1.55 lower (3.08 lower–0.02 lower)	-	4365 (5 RCTs)	⊕⊕⊕○ MODERATE	
Total adverse events	199 per 1,000	280 per 1,000 (243–324)	RR 1.41 (1.22–1.63)	3027 (2 RCTs)		

*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; RR: risk ratio; MD: mean difference.

GRADE Working Group grades of evidence.

High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.

Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.



different between the two groups (RR 1.00, 95% CI: 0.93–1.07, p = 0.93) (**Figure 3A**). There was no inconsistency factor across trials, indicating a statistical heterogeneity ($I^2 = 0\%$, p = 0.69).

Reporting Biases for the Primary Outcome

The visual assessment showed that there was a partial asymmetry in the funnel plot and contour-enhanced funnel (**Figures 4A,B**), while *p*-values (0.51 and 0.75) were found in the Egger's test and Begg's test in a dominant model, respectively, which indicated that no statistical significance was found (**Table 5**).

A Subgroup Analysis for the Primary Outcome

To investigate heterogeneity, we performed a subgroup analysis for the primary outcome. As depicted in **Table 6**, there was no substantial difference between the groups regarding mortality at day 28 across prespecified subgroups based on study design, patient population, the modality of RRT, and the presence of sepsis at randomization for the primary outcome.

TSA for the Primary Outcome

The trial sequential analysis showed that the required information size was 5,034 and the cumulative *Z*-curve crossed trial sequential monitoring boundaries for futility



Tests	Р
Begg's 1-tailed	0.37
Begg's 2-tailed	0.75
egger's 1-tailed	0.25
egger's 1-tailed	0.51

(Figure 3B), indicating that there is no difference between the eRRT and dRRT in terms of mortality at day 28 and no more studies were needed.

A Sensitivity Analysis for the Primary Outcome

To evaluate the potential effect of non-low bias studies on the robustness of data analysis, we performed a sensitivity analysis for the primary outcome by removing individual trials at a time with non-low bias in each domain. This sensitivity analysis produced similar results for the primary outcome (**Figure 5A**). Furthermore, we also conducted a sensitivity analysis by using the best-worst-case scenario analysis and worst-best-case scenario analysis to explore the influence of incomplete primary outcome data, which suggested that incomplete outcome data did not influence the results, either confirmed by the best-worst-case scenario analysis (RR 0.87, 95% CI: 0.68–1.11, p = 0.26, $I^2 = 85\%$) (**Figure 5B**) or by worst-best-case scenario analysis (RR 1.08, 95% CI: 0.85–1.36, p = 0.54, $I^2 = 84\%$) (**Figure 5C**), respectively.

Secondary Outcomes

All-Cause Mortality (at Days 60 and 90, in ICU and in Hospital)

Definitions for all-cause mortality included all-cause mortality at day 60, day 90, in an ICU, and in a hospital. The conventional meta-analysis showed that all mortality outcomes did not differ between eRRT and dRRT (Supplementary Digital Content— **Supplementary Figures S1A–D**), TSA for all-cause mortality at day 60 showed that the cumulative *Z*-curve touched neither a traditional boundary nor trial sequential monitoring boundaries, indicating that further studies with larger sample size are needed to confirm this result. TSA for all-cause mortality at day 90, in an ICU, and in a hospital were consistent with those reported in mortality at day 28 (Supplementary Digital Content—**Supplementary Figures S2A–D**).

The Rate of RRT

The rate of RRT was reported in 10 trials, including 5,069 participants and 4,064 events (6, 12, 13, 15, 16, 30, 33–36). The result demonstrated that the rate of RRT significantly increased in eRRT (RR, 1.50, 95% CI: 1.28–1.76, p < 0.00001, $I^2 = 96\%$) (Supplementary Digital Content—**Supplementary Figure S3A**). TSA showed that the cumulative *Z*-curve touched the traditional boundary, but not for the sequential monitoring boundary, suggesting that further studies with a larger sample size are needed to rule out possible false positives (Supplementary Digital Content—**Supplementary Digital** Content—**Supplementary Digital** Content—**Supplementary Digital**

Ventilator-Free Days, Vasoactive Agent-Free Days, and the Rate of RRT Dependence at Day 28

There was also no significant difference in ventilatorfree and vasoactive agents-free days between the two groups at day 28 (Supplementary Digital Content— **Supplementary Figures S4A,B**). About 7 of 12 trials (6, 12, 13, 16, 30, 34, 36) reported the rate of RRT dependence at day 28. The pooled analysis showed that the risk of RRT dependence at day 28 was not significantly different between the two groups (RR, 0.80, 95% CI: 0.50–1.29, p = 0.36, $I^2 = 58\%$) (Supplementary Digital Content—**Supplementary Figure S5A**), and the cumulative *Z*-curve did not touch a traditional boundary or trial sequential monitoring boundaries, indicating that further studies with a larger sample size are needed to confirm the result (Supplementary Digital Content—**Supplementary Figure S5B**).

The LOS of Survivors in ICU and Hospital

The meta-analysis from five of the included articles (6, 12, 15, 30, 33) showed that the LOS of survivors in an ICU (MD: -1.55 days; 95% CI: -3.08 to -0.02, p = 0.05, $I^2 = 29\%$) (Supplementary Digital Content—**Supplementary Figure S6A**) and the LOS of survivors in a hospital were significantly decreased in eRRT (MD: -2.74 days; 95% CI: -4.93 to -0.55, p = 0.01, $I^2=14\%$) (Supplementary Digital Content—**Supplementary Figure S6B**).

Adverse Events

Sean et al. (15) and Wald et al. (33) reported the total adverse events during the first 14 days, but the analysis was only relied on Sean's study because of Wald's too small trial. Sean et al. (15) reported that the adverse events included an association with renal-replacement therapy (hypotension, arrhythmia, seizure, bleeding, allergic reaction, decreased phosphate, decreased potassium, and decreased ionized calcium) and an association with the use of a dialysis catheter (pneumothorax or hemothorax, bleeding, thrombus, arterial puncture). The total adverse events of Wald et al. (33) include arrhythmia, hypotension, hemorrhage, hypocalcemia, ischemic bowel, and sepsis. Adverse events were significantly increased in eRRT (RR, 1.41, 95%CI: 1.22–1.63, p < 0.00001. Heterogeneity not applied) (Supplementary Digital Content-Supplementary Figure S7A), and it was confirmed by TSA (Supplementary Digital Content-Supplementary Figure S7B). However, the risk of bleeding, arrhythmia, and hypotension had no difference between the two groups (Supplementary Digital Content—Supplementary Figures S7C-E).

DISCUSSION

Conflicting results about the effect of eRRT vs. dRRT on patients with AKI exited for a long time, resulting in the optimal timing of RRT, which has been undecidable (37–39). Given the lack of quality evidence, more recently, two high-quality RCTs were published in NEJM (15) and Lancet (16), which compared the effects of eRRT vs. dRRT on critically ill patients with AKI. So, we did an updated systematic review with TSA.

In our meta-analysis, we found that there was no evidence to support the beneficial effects of eRRT on all-cause mortality at

TABLE 6	Subaroup	analysis	for all-caus	se mortality	at da	v 28.
	ousg.oup	a. 101. j 010	101 011 00404	50 11101 (0.110)		, _0.

Subgroup	No of study	No of p	oatients	Risk ratio (Bandom-effect	95% CI	I ²	Р
		eRRT	dRRT	model)			
Patient population							
≥100	8	2,458	2,463	0.99	0.93-1.07	0	0.88
<100	1	30	30	1.15	0.67-1.99	NA	0.61
RRT modality							
IHD	0						
CRRT only	4	217	221	1.02	0.84-1.24	0	0.83
Mixed	5	2,271	2,272	0.98	0.90-1.07	15	0.72
Presence of sepsis	s at randomization						
100%	1	246	242	1.07	0.87-1.31	NA	0.51
<100%	8	2,242	2,251	0.99	0.92-1.06	0	0.74
Study Design							
Single-center	2	142	149	0.89	0.59-1.33	40	0.56
Multi-center	7	2,346	2,344	1.01	0.94-1.08	0	0.88

A subgroup analysis based on the following items: reason for admission, presence of sepsis at randomization, patient population, RRT modality, sample size, study design. eRRT, early renal replacement therapy; dRRT, delayed renal replacement therapy; CRRT, continuous renal replacement therapy; IHD, intermittent hemodialysis.

days 28 and 90, as well as in a hospital and in an ICU. These results were further confirmed by a sensitivity analysis or the TSA. Our result was consistent with some previous analyses (40, 41). In the analysis by Fayad et al. (42), the proportion of patients who died on day 28 did not significantly differ between the two groups. And, the other meta-analyses (40, 43) had the same results as did in Fayad et al. (42). However, some other meta-analyses have drawn the opposite conclusion. Zou et al. (44) did a meta-analysis, which included 15 studies with 1,479 patients and found that eRRT decreased 28-day mortality, especially when it was started within 24 h after cardiac surgery in patients with AKI. Wang et al. (45) selected 51 studies (including 10 RCTs) with a total of 8,179 patients with AKI showed that patients receiving eRRT had a 25% reduction in all-cause mortality compared to those receiving dRRT. These inconsistent results could be explained by several factors as follows. First, the sample sizes enrolled were quite large in the meta-analysis by Zou et al. and Wang et al., but a significant heterogeneity of the included studies could not be ignored, which may affect the robustness of the results. Second, study by Zou et al. was conducted in patients with AKI who had undergone cardiac surgery only. As we all know that most patients undergoing cardiac surgery were associated with cardiac insufficiency, and RRT can reduce generalized congestion and decrease cardiac load resulting in proving cardiac dysfunction.

These inconsistencies added further uncertainty about the efficacy of eRRT in critically ill patients with AKI. In a traditional meta-analysis, the positive results were easy to be changed with more evidence being accumulated (17, 46). Therefore, we performed TSA, of which the results were able to verify our traditional meta-analysis results: all-cause mortality at days 28 and 90, as well as in a hospital and in an ICU, and most importantly, to say no more studies were needed. While TSA for all-cause mortality at day 60 indicated that further studies with

a larger sample size are needed to confirm this result, this may be related to the small sample size. In this respect, our analytic results of all-cause mortality at day 28, day 90, in a hospital, and in an ICU should be considered as convincing.

During our analysis, low degrees of heterogeneity were found in all-cause mortality at day 28 ($I^2 = 0\%$, p =0.69). As we all know, in addition to statistical heterogeneity, it also includes clinical heterogeneity and methodological heterogeneity. Therefore, we conducted subgroup analyses based on study design, patient population, the modality of RRT, and the presence of sepsis at randomization, and found no substantial difference between the groups regarding mortality at day 28. Sensitivity analyses also showed that missing data did not change the primary outcome. However, the definitions of eRRT and dRRT in each included study were different, which prevents us from performing relevant heterogeneity analysis. In addition, we could not evaluate all possible causes of heterogeneity, which may affect the accuracy of our results.

In our analysis, an indicator of safety—the risk of total adverse events increased in eRRT and TSA also confirmed the result, but there was no significant difference in the risk of bleeding, arrhythmia, hypotension, and hyperkalemia. The TSA result required further studies are needed to confirm these results. The inconsistency may be due to the inclusion of different studies for the analysis of these two results. Therefore, it is expected that the same studies are used simultaneously for these two indicators.

Our meta-analysis has the following strengths: (1) We prespecified our analytical plan and registered the study protocol with INPLASY to ensure the methodological quality of the review. (2) We selected RCTs published only in the last 10 years and included the latest published high-quality RCTs (15, 16). (3) Considering clinical heterogeneity especially due to differences in the definition of eRRT and dRRT, we performed a sensitivity analysis with the "best-worst-case" scenario and

Study or Subgroup Events Total Weight Ratio Study or Subgroup Events Total Weight M-H. Random. 95% CI 13.12 28-day mortality Barbar/2016 111 246 102 242 13.3% 1.07 (0.87, 1.31) Gaudy/2016 129 311 134 308 16.1% 0.95 (0.79, 1.43) Sean M 2020 538 1465 523 1462 58.7% 1.03 (0.33, 1.13) Srieswat2017 10 20 9 1.01 (0.94, 1.09) 1.01 (0.94, 1.09) Total events 858 851 Heterogeneity: Tau ² = 0.00; Ch ² = 3.84, df = 5 (P = 0.60); P = 0% Test for overail effect. Z = 0.26 (P = 0.79) Total (95% CI) 2212 2211 100.0% 1.01 (0.94, 1.09] Total events 685 651 1.07 (0.87, 1.31) 0.01 0.1 1.01 (0.94, 1.09] Total (95% CI) 2212 2211 100.0% 1.01 (0.94, 1.09] 0.01 0.1 1.01 (0.7, 1.31) Gaudry 2021 52 137 1.03 (0.87, 1.31)	Δ							
Shudy or Subgroup Events Total Weight MH, Random, 95%; Cl MH, Random, 95%; Cl Barbar2018 111 246 102 242 13.3% 1.07 (0.87, 1.31) Gaudry2016 129 311 134 0.95 (0.79, 1.45) Sean M 2020 538 4465 552 1.03 (0.83, 1.13) Sinswar2017 10 20 9 20 1.3% 1.11 (0.58, 2.14) Zarbock2016 34 112 448 119 4.3% 0.75 (0.53, 1.07) Subtocal (65% Cl) 2212 2211 100.0% 1.01 (0.94, 1.09) Total events 658 651 Heterogeneity: Tau ¹² = 0.00; Ch ² = 3.44, df = 5 (P = 0.60); P = 0% Test for vorall effect. Z = 0.26 (P = 0.79) Total events 658 651 Heterogeneity: Tau ¹² = 0.00; Ch ² = 3.44, df = 5 (P = 0.60); P = 0% Test for vorall effect. Z = 0.26 (P = 0.79) Total events 636 651 Barba2016 111 242 1.25% 1.07 (0.87, 1.31) Gaudry2015 129 311 34 36 (6, 1.13) 0.46 (0.41, 1.3) Gaudry201		early RRT		delayed RRT		Risk Ratio		Risk Ratio
13.12.22-day mortality Barbar/2016 111 246 102 242 13.3% 1.07 [0.87, 1.31] Gaudry2016 129 311 134 308 16.1% 0.55 [0.79, 1.43] Sean M 2020 538 1465 523 1462 58.7% 1.03 [0.33, 1.13] Shsawt2017 10 20 9.2 1.3% 0.75 [0.53, 1.07] Stabutcal (6%C) 2212 2211 100.0% 1.01 [0.94, 1.09] Total events 858 851 Heterogeneity: Tau* = 0.00; Ch* = 3.84, df = 5 (P = 0.60); P = 0% 1.01 [0.94, 1.09] Total events 858 651 Heterogeneity: Tau* = 0.00; Ch* = 3.84, df = 5 (P = 0.60); P = 0% 1.01 [0.94, 1.09] Total events 858 651 Heterogeneity: Tau* = 0.00; Ch* = 3.84, df = 5 (P = 0.60); P = 0% 1.07 [0.71, 1.31] Gaudry 0201 111 246 102 242 125% 1.07 [0.87, 1.31] Gaudry 0201 129 107 107 107 107 1.11 1.11 1.16 [0.67, 1.31] Gaudry 0201 129 109 100 0.5	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	CI M-H, Random, 95% CI
Barbar2018 111 246 102 242 13.3% 1.07 [0.87, 1.31] Gaudry2016 129 311 134 306 16.1% 0.95 [0.79, 1.45] Sean M 2020 538 1465 523 1462 58.7% 1.03 [0.93, 1.13] Srisawa2017 10 20 9 20 1.3% 1.11 [0.58, 2.14] Zarbock2016 34 112 48 119 4.3% 0.75 [0.53, 1.07] Total events 858 651 Heterogeneity: Tau ² = 0.00; Ch ² = 3.84, df = 5 (P = 0.60); P = 0% Test for overall effect Z = 0.26 (P = 0.79) Total events 858 651 Heterogeneity: Tau ² = 0.00; Ch ² = 3.84, df = 5 (P = 0.60); P = 0% Test for overall effect Z = 0.26 (P = 0.79) Total events 858 651 Heterogeneity: Tau ² = 0.00; Ch ² = 3.84, df = 5 (P = 0.60); P = 0% Test for overall effect Z = 0.26 (P = 0.79) Total events 858 651 Heterogeneity: Tau ² = 0.00; Ch ² = 3.84, df = 5 (P = 0.60); P = 0% Test for overall effect Z = 0.26 (P = 0.79) Total events 658 651 Heterogeneity: Tau ² = 0.00; Ch ² = 3.84, df = 5 (P = 0.60); P = 0% Test for overall effect Z = 0.26 (P = 0.79) Test for subcroup differences: Not acclicable B early RRT delayed RRT B adva/y 2021 52 137 63 141 11.5% 0.45 [0.79, 1.51] Gaudry 2021 52 137 63 141 11.5% 0.45 [0.79, 1.51] Jun2014 139 109 44 111 1.08% 0.39 [0.84, 1.27] Junation 2015 538 1485 523 1462 524 0.7% 0.00 [0.00, 0.08] Vaara2017 10 20 9 20 6.9% 0.01 [0.00, 0.08] Vaara2017 10 20 9 20 6.9% 0.01 [0.00, 0.08] Vaara2014 0 48 522 0.7% 0.01 [0.00, 0.08] Vaara2015 0 90 44 44 0.7% 0.01 [0.00, 0.09] Zarbock2016 34 112 48 119 10.6% 0.75 [0.53, 1.07] Total events 704 Events 704 Events 71 [P < 0.00001); P = 85% Test for overall effect Z = 1.17; Ch ² = 3.22, df = 1.17 (P < 0.0001); P = 85%; Cl Barbar2013 11 24 48 119 10.6% 0.75 [0.53, 1.07] Total events 1204 07 142 02 9 26 6.7% 1.15 [0.58, 7.13] Gaudry 2021 52 137 63 141 11.6% 0.85 [0.64, 1.13] Gaudry 2021 52 137 63 141 11.6% 0.85 [0.64, 1.13] Gaudry 2021 62 137 63 141 11.6% 0.85 [0.64, 1.13] Gaudry 2021 62 137 144 111 10.8% 0.95 [0.51, 1.53] Total events 1204 07 102 9 20 6.7% 122.86 [53, 1.35] Total events 1204 07 102 09 20 6.7% 122.86 [53, 1.35] Total events 120	13.1.2 28-day mortalit	У						
Gaudry2016 129 311 134 308 16.1% 0.05 [0.79, 1.15] Sean M 2020 538 1465 523 1462 58.7% 1.03 [0.39, 1.13] Sriaawa207 10 0 20 9 20 1.3% 1.13 [0.58, 1.13] Sriaawa207 10 20 9 20 1.3% 0.75 [0.53, 1.07] Total avents 858 851 Heterogeneity: Tau ² = 0.00; Ch ² = 3.64, df = 5 (P = 0.60); P = 0% Test for overall effect. Z = 0.26 (P = 0.79) Total avents 858 851 Heterogeneity: Tau ² = 0.00; Ch ² = 3.64, df = 5 (P = 0.60); P = 0% Test for overall effect. Z = 0.26 (P = 0.79) Total avents 858 851 Heterogeneity Tau ² = 0.00; Ch ² = 3.64, df = 5 (P = 0.60); P = 0% Test for overall effect. Z = 0.26 (P = 0.79) Total avents 858 851 Heterogeneity Tau ² = 0.00; Ch ² = 3.64, df = 5 (P = 0.60); P = 0% Test for overall effect. Z = 0.26 (P = 0.79) Test for overall effect. Z = 0.26 (P = 0.79) Test for overall effect. Z = 0.26 (P = 0.79) Test for overall effect. Z = 0.26 (P = 0.79) Test for overall effect. Z = 0.26 (P = 0.79) Test for overall effect. Z = 0.26 (P = 0.79) Test for overall effect. Z = 0.26 (P = 0.79) Test for overall effect. Z = 0.26 (P = 0.79) Test for overall effect. Z = 0.26 (P = 0.79) Test for overall effect. Z = 0.26 (P = 0.79) Test for overall effect. Z = 0.26 (P = 0.79) Test for overall offect. Z = 0.26 (P = 0.79) Test for overall effect. Z = 0.26 (P = 0.79) Test for overall status 2013 111 246 102 0.95 (0.94, 1.13] Gaudry 2021 538 1465 523 1462 13.4% 10.05 (0.93, 1.15] Sriaawa2071 10 20 9 20 6.9% 1111 (0.84, 1.09) Sriaawa2071 10 20 9 20 6.9% 1111 (0.84, 1.09) Total events 694 1173 Heterogeneity: Tau ² = 0.11; Ch ² = 7.22, df = 11 (P < 0.00001); P = 85% Total events 694 1173 Heterogeneity: Tau ² = 0.11; Ch ² = 7.22, df = 11 (P < 0.00001); P = 85% Total events 694 1173 Heterogeneity: Tau ² = 0.11; Ch ² = 7.22, df = 11 (P < 0.00001); P = 85% Total events 694 1173 Heterogeneity: Tau ² = 0.11; Ch ² = 0.26) Total events 694 1173 Heterogeneity: Tau ² = 0.11; Ch ² = 9.24, 1174 (M = 1.06 (M = 0.76), 1.05 (0.31, 1.31) Gaudry 2021 538 1465 523 1462 135% 10.01 (0.01 (0.0	Barbar2018	111	246	102	242	13.3%	1.07 [0.87, 1.31]	1 7
Lumiergui2018 36 58 35 60 6.3% 1.06 [0.79, 1.43] Sear M 2020 538 1465 523 1462 56.2% 1.03 [0.39, 1.13] Srisswat2017 10 20 9 20 1.3% 1.11 [0.58, 2.14] Zarbock2016 34 112 44 119 4.3% 0.75 [0.53, 1.07] Subtocla (95% CI) 2212 2211 100.0% 1.01 [0.94, 1.09] Total events 858 851 Heterogeneity: Tau ² = 0.00; Ch ² = 3.64, df = 5 (P = 0.60); P = 0% Test for overall effect: Z = 0.26 (P = 0.79) Total events 858 851 Heterogeneity: Tau ² = 0.00; Ch ² = 3.64, df = 5 (P = 0.60); P = 0% Test for overall effect: Z = 0.26 (P = 0.79) Total events 858 851 Heterogeneity: Tau ² = 0.00; Ch ² = 3.64, df = 5 (P = 0.60); P = 0% Test for overall effect: Z = 0.26 (P = 0.79) Total events 858 851 Heterogeneity: Tau ² = 0.00; Ch ² = 3.64, df = 5 (P = 0.60); P = 0% Test for overall effect: Z = 0.26 (P = 0.79) Total events 958 CI Be early RRT delayed RRT 816 Katio Risk Ratio Risk Ratio Be arry RRT delayed RRT 81, 15% 0.05 [0.64, 1.31] Gaudry 2021 52 137 63 141 11.5% 0.05 [0.64, 1.31] Gaudry 2021 52 137 63 141 11.5% 0.05 [0.64, 1.31] Gaudry 2021 52 137 63 144 11.5% 0.05 [0.64, 1.13] Gaudry 2021 538 1465 523 1462 13.4% 1.03 [0.39, 1.13] Srisswat2017 10 20 9 20 6 60% 0.7% 0.00 [0.00, 0.68] Vaaraz014 0 48 52 22 0.7% 0.01 [0.00, 0.08] Vaaraz014 0 48 52 22 0.7% 0.01 [0.00, 0.08] Vaaraz014 0 48 523 1462 522 0.7% 0.01 [0.00, 0.08] Vaaraz014 0 48 523 126 22 0.7% 0.01 [0.00, 0.08] Vaaraz014 0 48 523 1462 522 0.7% 0.01 [0.00, 0.68] Vaaraz014 0 14 41 112 48 119 10.6% 0.75 [0.53, 1.07] Total (95% CI) 2728 2995 100.0% 0.47 [0.68, 1.11] Gaudry 2021 62 137 63 141 11.6% 0.020 [0.64, 1.27] Heterogeneity: Tau ² = 0.11; Ch ² = 7.322, df = 11 (P < 0.00001); P = 85% Test for overall effect: Z = 0.12; Ch ² = 242 12.6% 1.07 [0.63, 1.07] Gaudry 2021 62 137 63 141 12 48 119 10.6% 0.75 [0.53, 1.07] Total (95% CI) 2728 2995 100.0% 0.47 [0.68, 1.11] Gaudry 2021 62 137 63 141 11.6% 0.020 [0.64, 1.27] Heterogeneity: Tau ² = 0.11; Ch ² = 0.51, df = 11 (P < 0.00001); P = 85% Total events 1 204 0 97 1 Vaaraz014 0 120 9 9 00	Gaudry2016	129	311	134	308	16.1%	0.95 [0.79, 1.15]	l •
Sean M 2020 538 1465 523 1462 58.7% 1.03 [0.93, 1.13] Srisswet2017 10 20 9 20 1.3% 1.11 [0.58, 2.14] Zarbock2016 34 112 48 119 4.3% 0.75 [0.53, 1.07] Total (95% C) 2212 2211 100.0% 1.01 [0.94, 1.09] Total (95% C) 2212 2211 100.0% 1.01 [0.94, 1.09] Budy cor Subgroup Events Total Events Total Velop H HH. Random .95% CI Barbar2018 111 246 102 242 12.5% 1.07 [0.87, 1.31] Gaudry201 52 137 66 114 115% 0.085 [0.64, 1.13] Gaudry201 52 137 66 114 111 0.08 0.09[0.64, 1.27] Lumiergui2016 336 146 52 52 0.7% 0.01 [0.00, 0.69] Vaara2014 0 48 52 52 0.7% 0.01 [0.00, 0.68] 1.11] Total (95% C) 2223 2655 100.0% 0.37 [0.68, 1.11] Total (95% C) 223 11 134 308 12.2% 0.055 [0.73, 1.5] Barbar2010 111 246 102 242 12.25% 1.07 [0.67, 1.31] Gaudry2014 139 109 44 111 10.5% 0.09 [0.64, 1.27] Lumiergui2016 336 1465 523 1462 13.5% 1.14 148 109 10.06 0.168] Total (95% C) 2728 2655 100.0% 0.37 [0.68, 1.11] Total events 964 117 242 10.24% 12.05% 1.15 [0.67, 1.99] Zarbock2016 33 1465 523 1462 13.5% 1.14 148 109 10.03 (0.44, 1.27] Total (95% C) 2728 2655 100.0% 0.75 [0.53, 1.07] Total (95% C) 2728 2655 100.0% 0.75 [0.53, 1.07] Total (95% C) 2728 2655 100.0% 0.75 [0.53, 1.07] Total (95% C) 27	Lumlertgul2018	36	58	35	60	6.3%	1.06 [0.79, 1.43]	
Srieswar2017 10 20 9 20 1.3% 111 [0.58, 2.14] Zarbock2016 34 112 44 119 4.3% 0.75 [0.53, 1.07] Subtocal (95% CI) 2212 2211 100.0% 1.01 [0.94, 1.09] Total events 858 851 Heterogeneity: Tau ² = 0.00; Chi ² = 3.64, df = 5 (P = 0.60); P = 0% Test for overall effect: Z = 0.26 (P = 0.79) Total events 865 851 Heterogeneity: Tau ² = 0.00; Chi ² = 3.64, df = 5 (P = 0.60); P = 0% Test for overall effect: Z = 0.00; Chi ² = 3.64, df = 5 (P = 0.60); P = 0% Test for overall effect: Z = 0.00; Chi ² = 3.64, df = 5 (P = 0.60); P = 0% Test for overall effect: Z = 0.00; Chi ² = 3.64, df = 5 (P = 0.60); P = 0% Test for overall effect: Z = 0.00; Chi ² = 3.64, df = 5 (P = 0.60); P = 0% Test for overall effect: Z = 0.00; Chi ² = 3.64, df = 5 (P = 0.60); P = 0% Test for overall effect: Z = 0.00; Chi ² = 3.64, df = 5 (P = 0.60); P = 0% Test for overall effect: Z = 0.26 (P = 0.79) Test for overall effect: Z = 0.26 (P = 0.79) Test for overall effect: Z = 0.26 (P = 0.79) Test for overall effect: Z = 0.26 (P = 0.79) Subtor Subgroup Events Total Events Total Weight MH, Random .95% CI Barbar2016 111 246 102 242 125% 1.07 (0.87, 1.31) Gaudy 2021 52 137 63 141 11.5% 0.65 (0.74, 1.33] Gaudy 2016 128 311 134 308 12.7% 0.05 (0.04, 1.27) Lumiergu/2018 36 68 35 60 11.4% 1.06 (0.79, 1.43] Sean M.2020 538 1465 523 1462 13.4% 1.06 (0.79, 1.43] Sean M.2020 538 1465 523 1462 11.4% 1.06 (0.79, 1.43] Total events 964 1173 Heterogeneity: Tau ² = 0.1; Chi ² = 3.22, df = 11 (P < 0.00001); P = 85% Test for overall effect: Z = 1.12 (P = 1.28) Total events 964 1173 Heterogeneity: Tau ² = 0.1; Chi ² = 3.32, df = 11 (P < 0.00001); P = 85% Test for overall effect: Z = 0.11; Chi ² = 6.85 1, df = 11 (P < 0.00001); P = 85% Test for overall effect: Z = 0.11; Chi ² = 0.81 (M = 1.10, 0.33, 1.31] Heterogeneity: Tau ² = 0.11; Chi ² = 0.81 (M = 1.10, 0.45, 1.13] Gaudy 2016 52 147 42 13.5% 1.11 (0.48, 0.25 (0.78, 1.13] Heterogeneity: Tau ² = 0.11; Chi ² = 0.81, df = 11 (P < 0.00001); P = 84% Natazeria field: Z = 0.11; C	Sean M 2020	538	1465	523	1462	58.7%	1.03 [0.93, 1.13]	
Zarbock2016 34 112 48 119 4.3% 0.75 [0 53, 107] Total (95% C) 2212 2211 100.0% 1.01 [0.94, 1.09] Total (95% C) 2212 2211 100.0% 1.01 [0.94, 1.09] Budy or Subprove Events Total Events Total Velow MH HA Random .95% CI Barbar2016 111 246 102 242 12.5% 1.07 [0.07, 1.31] Gaudry 2021 52 137 66 114 115% 0.085 [0.64, 1.13] Gaudry 2021 52 137 66 114 115% 0.085 [0.64, 1.13] Gaudry 2021 52 137 66 114% 1.106 [0.79, 1.43] Sean M 2020 538 1465 523 1462 13.4% 1.03 [0.38, 1.13] Sisawa2021 7 10 20 9 20 6.9% 1.111 [0.58, 2.14] Tukaram E2013 0 102 106 106 0.7% 0.001 [0.00, 0.08] Wara2014 0 48 52 52 0.7% 0.01 [0.00, 0.08] Wara2014 0 48 52 52 0.7% 0.01 [0.00, 0.08] Vara2014 0 48 52 52 0.7% 0.01 [0.00, 0.08] Vara2014 0 48 52 52 0.7% 0.01 [0.00, 0.68] Tukaram E2013 0 122 102 106 106 0.7% 0.007 [0.00, 1.15] Gaudry 201 52 137 63 141 11.0% 0.085 [0.64, 1.13] Total (95% C) 2228 2695 100.9% 0.37 [0.68, 1.11] Total events 964 1173 Heist Ratio Risk Ratio Study or Subgroup Events Total Events Total Weight MH Random .95% CI Barbar2013 111 246 102 242 12.26% 1.07 [0.87, 1.31] Gaudry 201 52 137 63 141 11.0% 0.085 [0.64, 1.13] Total (95% C) 2728 2695 100.9% 0.37 [0.68, 1.11] Total events 1204 020 538 1465 523 1462 13.5% 1.148, 1.048 [0.44, 1.13] Fist Ratio Revers Total Events Total Events Total Weight MH Random .95% CI Barbar2013 112 48 119 10.5% 0.000 [0.44, 1.27] Total (95% C) 2728 2695 100.9% 0.57 [0.53, 1.07] Total (95% C) 2728 2695 100.9% 0.58 [0.56, 7.13] Gaudry 2016 33	Srisawat2017	10	20	9	20	1.3%	1.11 [0.58, 2.14]	
Subtocal (95% CI) 2212 2211 100.0% 1.01 [0.94, 1.09] Total events 858 851 Heterogeneity: Tau ² = 0.00; Chi ² = 3.64, df = 5 (P = 0.60); P = 0% Total events 658 851 Heterogeneity: Tau ² = 0.00; Chi ² = 3.64, df = 5 (P = 0.60); P = 0% Total events 658 851 Heterogeneity: Tau ² = 0.00; Chi ² = 3.64, df = 5 (P = 0.60); P = 0% Test for overall effect: Z = 0.26 (P = 0.79) Total events 668 early RRT delayed RRT Barbarciola Feerory RRT Barbarciola 102 242 Study or Subgroup Events Total Weight MH. Random.35% CI MH. Random.35% CI Barbarciola 38 35 601 1.14% 1.06 (D87, 1.13) Gaudy 2021 129 311 134 308 1.25% 1.01 (D8, 1.211) Junz2014 38 102 1.63% 0.03 (D80, 1.11) 1.01 1.01 Varaz014 0 48 52 2.07% 0.01 (D00, 0.06)	Zarbock2016	34	112	48	119	4.3%	0.75 [0.53, 1.07]	
Total events 858 851 Heterogeneity: Tau ² = 0.00; Ch ² = 3.64, df = 5 (P = 0.60); P = 0%; Test for overall effect: Z = 0.28 (P = 0.79) Total events 858 Study or subgroup Events Total events 616 (P = 0.79) Test for overall effect: Z = 0.28 (P = 0.79) Test for subcroup differences: Not anolicable Berbar2018 111 246 102 242 12.5% Barbar2018 111 246 102 242 12.5% Gaudry 2021 52 137 63 141 11.5% Gaudry 2021 52 314 425 32.14% Jumart Hard State 10.3 0.98 (1.13) Sene M 2020 538 1465 52.3 1462 13.4% 1.03 (0.97, 1.13) Sindawdro 2016 129 20 6.5% 1.01 (0.00, 0.16) Vararability 117 30 00 (0.00, 0.16) 10.00, 0.16 Vararability 117 31 30 8.12, 7% 0.56 (0.78, 1.13) Jumart Hard 11 10 246 102 242 12.5% 0.01 (0.00, 0.16) Vararability 113 30 8.11, 11 (0.58, 2.14) Total (95% Ch) 2228 22865 100.0% 0.75 (0.53, 1.07) Test for overall effect: Z = 1.12 (P = 0.26) C Hard Random 55% Cl Barbar2016 111 1 246 102 242 12.6% 1.0	Subtotal (95% CI)		2212		2211	100.0%	1.01 [0.94, 1.09]	
Heterogeneity: Tau" = 0.00; Chi" = 3.64, df = 5 (P = 0.60); P = 0% Total events 858 851 Heterogeneity: Tau" = 0.00; Chi" = 3.64, df = 5 (P = 0.60); P = 0% Test for overall effect: Z = 0.26 (P = 0.79) Total events 70 subgroup Events Total Events Total Weight M-H. Random, 95% Cl Barbar2016 111 246 102 242 12.5% 1.07 (0.87, 1.31] Gaudy 2021 52 137 63 141 11.5% 0.85 (0.64, 1.13) Gaudy 2021 52 137 63 141 11.5% 0.85 (0.64, 1.13) Gaudy 2021 52 137 63 141 11.5% 0.85 (0.64, 1.13) Gaudy 2021 52 137 63 141 11.5% 0.85 (0.64, 1.13) Gaudy 2021 52 137 63 141 11.5% 0.95 (0.79, 1.15) Jun2014 39 109 44 111 10.8% 0.90 (0.64, 1.27) Total events 964 1173 Heterogeneity: Tau" = 0.11; Chi" = 7.82, df = 11 (P < 0.0001); P = 85% Total events 964 1173 Heterogeneity: Tau" = 0.11; Chi" = 7.82, df = 11 (P < 0.0001); P = 85% Total events 964 1173 Heterogeneity: Tau" = 0.11; Chi" = 7.82, df = 11 (P < 0.0001); P = 85% Test for overall effect: Z = 0.26) C C early RRT delayed RRT Total events 964 1173 Heterogeneity: Tau" = 0.11; Chi" = 7.82, df = 11 (P < 0.0001); P = 85% Test for overall effect: Z = 0.26) C early QRT delayed RRT Total events 964 1173 Heterogeneity: Tau" = 0.11; Chi" = 7.82, df = 11 (P < 0.0001); P = 85% Test for overall effect: Z = 0.26) C early QRT delayed RRT Total events 964 1113 Heterogeneity: Tau" = 0.11; Chi" = 7.82, df = 11 (P < 0.00001); P = 85% Test for overall effect: Z = 0.12 (P = 0.26) C early QRT delayed RRT Total events 964 111 0.5% 0.35 (0.78, 1.15] Jun2014 39 109 04 44 111 1.6% 0.35 (0.64, 1.13] Gaudy/2015 10 09 00 04 40 07% 12.96 [1.41, 1.332, 2.43] Total events 964 1113 Heterogeneity: Tau" = 0.11; Chi" = 7.82, 1462 12.65% Total events 964 1113 Heterogeneity: Tau" = 0.11; Chi" = 0.81; df = 11 (P < 0.00001); P = 85% Total events 964 111 0.6% 0.30 (0.64, 1.71] Gaudy/2016 129 311 134 308 12.6% 10.35 (0.73, 1.15] Heterogeneity: Tau" = 0.11; Chi" = 0.81; df = 11 (P < 0.00001); P = 85% Total events 964 1110 0.5% 0.57 (0.33, 1.07] Heterogeneity: Tau" = 0.11; Chi" = 0.81;	Total events	858		851				
Test for overall effect: Z = 0.26 (P = 0.79) Total (95% Cl) 2212 2211 100.0% 1.01 [0.94, 1.09] Total events 858 851 Heterogeneity: Tau* 0.00; Chi = 3.64, df = 5 (P = 0.50); P = 0% Test for overall effect: Z = 0.26 (P = 0.79) Test for subcruo differences: Not anolicable Barbar2016 111 246 102 242 12.5% 107 [0.87, 1.31] Gaudry 2021 52 137 63 414 11.5% 0.85 [0.64, 1.13] Gaudry 2021 52 137 63 414 11.5% 0.95 [0.57, 1.15] Jun2014 39 109 44 111 10.8% 0.90 [0.64, 1.27] Uumiertgu2018 36 58 35 60 11.4% 1.08 [0.79, 1.43] Srisawa2017 10 20 9 20 6.5% 1.11 [0.58, 2.14] Total (95% Cl) 2728 2695 100.0% 0.87 [0.68, 1.11] Total (95% Cl) 2728 2695 100.0% 0.87 [0.68, 1.11] Total events 964 1173 Heterogeneity: Tau* 0.11; ChP = 73.22, df = 11 (P < 0.00001); P = 85% Test for overall effect: Z = 1.12 (P = 0.26) C erty RRT delayed RRT Risk Ratio Study or Subgroup Events Total Events Total Weight MH. Random, 95% Cl Barbar2016 111 246 102 242 12.5% 10.70 [0.68, 1.11] Total events 964 1173 Heterogeneity: Tau* 0.11; ChP = 73.22, df = 11 (P < 0.00001); P = 85% Test for overall effect: Z = 1.12 (P = 0.26) C erty RRT delayed RRT Risk Ratio Study or Subgroup Events Total Events Total Weight MH. Random, 95% Cl Barbar2016 111 246 102 242 12.6% 10.77 [0.68, 1.11] Heterogeneity: Tau* 0.11; ChP = 73.22, df = 11 (P < 0.00001); P = 85% Test for overall effect: Z = 1.12 (P = 0.26) C erty RRT delayed RRT Risk Ratio Study or Subgroup Events Total Events Total Weight MH. Random, 95% Cl Barbar2016 31 112 448 119 10.6% 0.05 [0.78, 1.15] Jun2014 39 010 44 111 10.8% 0.05 [0.64, 1.13] Gaudry2015 12 02 131 134 308 12.8% 0.35 [0.79, 1.16] Barbar2016 31 412 48 119 10.5% 0.37 [0.63, 1.07] Total (95% Cl) 2728 22905 100.0% 10.8 [0.64, 1.13] Total events 102 102 016 00 44 0.7% 8215.6[61, 41.13] Total events 102 102 016 00 44 0.7% 825.15.69, 1409.10] Vara2015 30 013 30 8.04% 1.15 [0.67, 1.59] Total events 102 102 016 00 44 0.7% 825.15.69, 1409.10] Vara2014 49 418 0 52 0.7% 104.29 [6.56, 1655.77] Vara2014 49 48 48 0 52 0.7% 104.	Heterogeneity: $Tau^2 = 0$	0.00: Chi ²	= 3.64.	df = 5 (P)	= 0.60)	$ ^{2} = 0\%$		
Total (95% CI) 2212 2211 100.0% 1.01 [0.94, 1.09] Total events 858 851 Heterogeneily: Tau"a 0.00; Chi" = 3.64, df = 5 (P = 0.60); P = 0% 0.01 0.1 0.1 10 Test for overall effect; 2 = 0.26 (P = 0.79) 0.01 0.1 0.1 0.1 0.1 0.1 Test for overall effect; 2 = 0.26 (P = 0.79) Test for overall effect; 2 = 0.26 (P = 0.79) Endry RT Galady 201 62 (P = 0.79) Test for subgroup Events Total events Total events Total events M-H. Random. 95% CI Barbar2018 111 246 102 242 12.5% 1.07 [0.87, 1.31] Gaudry 2016 129 311 134 308 10.4% 1.06 [0.79, 1.43] Sean M 2020 538 1465 52.3 1462 1.4% 1.06 [0.00, 0.09] Vara2014 0 48 52 52 0.7% 0.01 [0.00, 0.09] Vara2015 0 90 44 40 7% 0.01 [0.00, 0.09] Vara2014 0 48 52 52 0.7% 0.01 [0.00, 0.09] </td <td>Test for overall effect: 7</td> <td>7 = 0.26 (F</td> <td>P = 0.79</td> <td>3)</td> <td></td> <td>,</td> <td></td> <td></td>	Test for overall effect: 7	7 = 0.26 (F	P = 0.79	3)		,		
Total (95% CI) 2212 2211 100.% 1.01 [0.94, 1.09] Total (95% CI) 858 851 Heterogeneity: Tau" = 0.00; CI" = 3.64, di 5 (P = 0.60); P = 0% 0.01 0.1 0.1 10 100 Test for subcroue differences: Not acolicable early RRT delayed RRT Risk Ratio Risk Ratio MH. Random, 95% CI Barbar2018 111 246 102 242 12.5% 1.07 [0.87, 1.31] Gaudry 2021 52 137 63 141 11.5% 0.86 [0.64, 1.13] Gaudry 2026 528 1465 523 1462 1.27% 0.95 [0.79, 1.15] Juniergul2018 36 58 50 1.14% 1.06 [0.79, 1.43] Sean M 2020 538 1465 523 1462 1.34% 1.03 [0.93, 1.13] Srissware2017 10 20 9.20 6.9% 1.11 10.58, 2.14 1.00 Vaara2014 0 48 52 52 0.7% 0.01 [0.00, 0.08] 0.41 0.41 0.41 0.41 0.41 0.41 0.41 0.41 0.41		- 0.20 (1	0.70	~/				
Total events 858 851 Bath Trill Total events 856 851 Heterogeneily: Tau ² = 0.00; Ch ² = 3.64, df = 5 (P = 0.60); P = 0%	Total (95% CI)		2212		2211	100.0%	1.01 [0.94, 1.09]	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Total events	858		851				
1 absolution 1 absolution 1 absolution 0 absolution <td< td=""><td>Heterogeneity: $Tau^2 = ($</td><td>0000 0 000 Chi2</td><td>= 3.64</td><td>df = 5 (P)</td><td>= 0.60</td><td>$1^{2} = 0\%$</td><td></td><td></td></td<>	Heterogeneity: $Tau^2 = ($	0000 0 000 Chi2	= 3.64	df = 5 (P)	= 0.60	$1^{2} = 0\%$		
Test for subproup Early RRT delayed RRT Risk Ratio Risk Ratio B early RRT delayed RRT Risk Ratio Risk Ratio Barbar2018 111 246 102 242 12.5% 1.07 [0.87, 1.31] Gaudry 2021 52 137 63 141 11.5% 0.89 [0.79, 1.15] Junz014 39 109 44 111 0.8% 0.99 [0.64, 1.27] Lumilergui2018 36 58 56 0.11.4% 1.08 [0.09, 1.15] Junz014 0 9 20 6.9% 1.11 [0.58, 2.14] Vaara2014 0 48 52 52 0.7% 0.01 [0.00, 0.16] Vaara2014 0 48 52 52 0.7% 0.01 [0.00, 0.16] Vaara2014 0 48 119 1.06% 0.75 [0.53, 1.07] 10 Total (95% CI) 2722 2095 10.0% 0.87 [0.68, 1.11] 0.01 0.1 0.01 0.1 Study or Subgroup Fverts Total (95% CI) 2722 2695 10.0% 0.87 [0.68, 1.13] <td>Test for overall effect: 7</td> <td>7 – 0 26 /I</td> <td>= 0.07</td> <td>ui – 0 (i</td> <td>- 0.00)</td> <td>,1 = 070</td> <td></td> <td>0.01 0.1 1 10 100</td>	Test for overall effect: 7	7 – 0 26 /I	= 0.07	ui – 0 (i	- 0.00)	,1 = 070		0.01 0.1 1 10 100
B early RRT Total Events Total Weight MH. Random, 95% CI M.H. Random, 95% CI Barbar2018 111 246 102 242 12.5% 0.95 (0.79, 1.31) Gaudry 2021 129 311 134 308 12.7% 0.95 (0.79, 1.15) Jun2014 39 109 44 111 10.8% 0.90 (0.64, 1.27) Lumiertgul2018 36 58 36 60 11.4% 1.06 (0.79, 1.43) Seam X0200 538 1465 523 1462 1.03 (0.93, 1.13) Srisawat2017 10 20 9 20 6.9% 1.11 (0.58, 2.14) Tukaram E2013 0 102 12 38 60 1.14% 1.06 (0.79, 1.43) Zarbock2016 34 112 48 119 10.6% 0.76 (0.53, 1.07) Test for overall effect: Z = 1.12 (P = 0.28) 2728 2695 100.0% 0.87 (0.68, 1.11) Risk Ratio Barbar2018 111 246 102 242 12.6% 1.07 (0.87, 1.31) 0.01 0.1<	Test for subgroup differ	2 = 0.20 (r	ot appli) Pabla				early RRT delayed RRT
Study or Subgroup Events Total Weight MH. Random 95% CI MH.H. Random 95% CI Barbar2018 111 246 102 242 12.5% 1.07 (0.87, 1.31) HH. Random 95% CI Gaudy 2021 52 137 63 141 11.5% 0.85 (0.64, 1.13) HH. Random 95% CI Gaudy 2016 129 311 134 308 12.7% 0.95 (0.79, 1.15) Hill Hill 1.08% 0.90 (0.64, 1.27) Jumiergul2018 36 58 36 1.14% 1.06 (0.79, 1.43) Height MH 1.11 (0.58, 2.14) Sean M 2020 538 1465 523 1462 13.4% 1.03 (0.93, 1.13) Sriswat2017 10 20 9 20.6 6.9% 0.01 (0.00, 0.08) Hill Height MH 110 (0.56, 0.165, 1.09) Vaara2014 0 48 52 0.7% 0.01 (0.00, 0.16) Height MH Height MH <t< td=""><td>R</td><td>ences. No</td><td></td><td>delaver</td><td></td><td></td><td>Bick Batio</td><td>Pick Potio</td></t<>	R	ences. No		delaver			Bick Batio	Pick Potio
Judy of Study of	Study or Subgroup	Evonto		Evonto	Total	Mojaht	M H Bandom 05% C	MH Bandom 95% Cl
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Study of Subgroup	Events		Events	10121	40.5%	<u>мі-п, капцоіп, 95% с</u>	M-H, Randolli, 95% Cl
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Barbarzo 18	50	240	102	242	12.5%	1.07 [0.67, 1.31]	-
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Gaudry 2021	100	2 137	124	141	10.7%	0.05 [0.04, 1.15]	1
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Gaudry2018	128	3 311 0 100	134	300	10.00/	0.95 [0.79, 1.15]	
Luffler(gul2/16) 36 56 33 60 11.4% 1.06 [0.79, 1.43] Sean M 2020 538 1465 523 1462 13.4% 1.03 [0.93, 1.13] Srisawat2017 10 20 9 20 6.9% 1.11 [0.68, 2.14] Tukaram E2013 0 102 106 106 0.7% 0.00 [0.00, 0.09] Vara2014 0 48 52 52 0.7% 0.01 [0.00, 0.09] XIA 2019 15 30 13 30 8.1% 1.15 [0.67, 1.99] Zarbock2016 34 112 48 119 10.6% 0.75 [0.53, 1.07] Total (95% CI) 2728 2695 100.0% 0.87 [0.68, 1.11] Total events 964 1173 Heterogeneity: Tau ² = 0.11; Chi ² = 73.22, df = 11 (P < 0.00001); P = 85% Test for overall effect: Z = 1.12 (P = 0.26) C Study or Subgroup Events Total Events Total Weight M-H. Random, 95% CI Barbar2018 111 246 102 242 12.6% 1.07 [0.87, 1.31] Gaudry 2021 52 137 63 141 11.6% 0.85 [0.64, 1.13] Gaudry 2021 52 137 63 141 11.6% 0.95 [0.64, 1.13] Gaudry 2021 52 137 63 144 111 0.8% 0.90 [0.64, 1.27] Jun2014 39 109 44 111 10.8% 0.90 [0.79, 1.15] Jun2014 39 109 44 4111 10.8% 0.90 [0.79, 1.15] Jun2014 39 109 44 4111 10.8% 0.90 [0.79, 1.13] Gaudry 2021 52 137 63 142 13.5% 1.03 [0.93, 1.13] Gaudry 2021 52 137 63 141 11.6% 0.95 [0.79, 1.15] Jun2014 39 109 44 4111 10.8% 0.90 [0.64, 1.27] Lumlertgul2018 36 58 35 60 11.4% 1.06 [0.79, 1.43] Sean M 2020 538 1465 523 1462 13.5% 1.03 [0.93, 1.13] Sean M 2020 538 1465 523 1462 13.5% 1.03 [0.93, 1.13] Sean M 2020 538 1465 523 1462 13.5% 1.03 [0.93, 1.13] Sean M 2020 538 1465 523 1462 13.5% 1.03 [0.93, 1.13] Sean M 2020 538 1465 523 1462 13.5% 1.03 [0.93, 1.13] Sean M 2020 538 1465 523 1462 13.5% 1.03 [0.93, 1.13] Sean M 2020 538 1465 523 1462 13.5% 1.03 [0.93, 1.13] Srisawat2017 10 20 9 20 6.7% 1.11 [0.56, 1.49] 10 XiA 2019 15 30 13 30 8.0% 1.15 [0.67, 1.99] XiA 2019 15 30 13 30 8.0% 1.15 [0.67, 1.99] XiA 2019 15 30 13 30 8.0% 1.15 [0.67, 1.99] XiA 2019 15 30 13 30 8.0% 1.15 [0.67, 1.99] Zarbock2016 34 112 48 119 10.5% 0.75 [0.53, 1.07] Total (95% CI) 2728 2695 100.0% 1.08 [0.85, 1.36] Total events 1204 971 Heterogeneity: Tau ² = 0.11; Chi ² = 69.61, df = 11 (P < 0.00001); I ² = 84% Test for overall effect: 2 -0.51 (P = 0.54)	Junz014	38	5 109	44	111	10.0%	0.90 [0.64, 1.27]	+
Setart M 2020 538 1465 523 1462 103	Lumiertgui2018	500	0 00	30	1460	11.4%	1.06 [0.79, 1.43]	L Contraction of the second se
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Sean M 2020	530	0 1400	523	1462	13.4%	1.03 [0.93, 1.13]	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Silsawat2017	10	20	9	20	0.9%	1.11 [0.58, 2.14]	←
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Tukaram E2013	0	102	106	106	0.7%	0.00 [0.00, 0.08]	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Vaara2014	U O	48	52	52	0.7%	0.01 [0.00, 0.16]	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			90	44	44	0.7%	0.01 [0.00, 0.09]	·
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	XIA 2019	15	30	13	30	8.1%	1.15 [0.67, 1.99]	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Zarbock2016	34	112	48	119	10.6%	0.75 [0.53, 1.07]	_
Total events 964 1173 Heterogeneity: Tau ² = 0.11; Chi ² = 73.22, df = 11 (P < 0.00001); l ² = 85% Test for overall effect: $Z = 1.12$ (P = 0.26) C C early RRT delayed RRT Risk Ratio Study or Subgroup Events Total Events Total Weight M-H. Random, 95% Cl M-H. Random, 95% Cl Barbar2018 111 246 102 242 12.6% 1.07 [0.87, 1.31] Gaudry 2021 52 137 63 141 11.6% 0.85 [0.64, 1.13] Gaudry 2016 129 311 134 308 12.8% 0.95 [0.79, 1.15] jun2014 39 109 44 111 10.8% 0.90 [0.64, 1.27] Lumlertgul2018 36 58 35 60 11.4% 1.06 [0.79, 1.43] Sen M 2020 538 1465 523 1462 13.5% 1.03 [0.93, 1.13] Srisawat2017 10 20 9 20 6.7% 1.11 [0.58, 2.14] Tukaram E2013 102 102 0 106 0.7% 212.96 [13.41, 3382.83] Vaara2014 48 48 0 52 0.7% 104.92 [6.65, 1655.79] Wald2015 90 90 0 44 0.7% 89.51 [5.69, 1409.10] XlA 2019 15 30 13 30 8.0% 1.15 [0.67, 1.99] Zarbock2016 34 112 48 119 10.5% 0.75 [0.53, 1.07] Total events 1204 971 Heterogeneity: Tau ² = 0.11; Chi ² = 69.61, df = 11 (P < 0.00001); l ² = 84% Test for overall effect: Z = 0.61 (P = 0.54)	Total (95% CI)		2728		2695	100.0%	0.87 [0.68, 1.11]	•
Heterogeneity: Tau ² = 0.11; Chi ² = 73.22, df = 11 (P < 0.00001); P = 85% Test for overall effect: $Z = 1.12$ (P = 0.26) C early RRT delayed RRT RIsk Ratio Study or Subgroup Events Total Events Total Weight M-H, Random, 95% Cl Barbar2018 111 246 102 242 12.6% 1.07 [0.87, 1.31] Gaudry 2021 52 137 63 141 11.6% 0.85 [0.64, 1.13] Gaudry 2016 129 311 134 308 12.8% 0.95 [0.79, 1.15] jun2014 39 109 44 111 10.8% 0.90 [0.64, 1.27] Lumlertgul2018 36 58 35 60 11.4% 1.06 [0.79, 1.43] Sean M 2020 538 1465 523 1462 13.5% 1.03 [0.93, 1.13] Srisawat2017 10 20 9 20 6.7% 1.11 [0.58, 2.14] Tukaram E2013 102 102 0 106 0.7% 212.96 [13.41, 3382.83] Vaara2014 48 48 0 52 0.7% 104.92 [6.65, 1655.79] Wald2015 90 90 0 44 0.7% 89.51 [5.69, 1409.10] XIA 2019 15 30 13 30 8.0% 1.15 [0.67, 1.99] Zarbock2016 34 112 48 119 10.5% 0.75 [0.53, 1.07] Total (95% Cl) 2728 2695 100.0% 1.08 [0.85, 1.36] Total (95% Cl) 2728 2695 10	Total events	964		1173				
Test for overall effect: $Z = 1.12$ (P = 0.26) C C C C C C C C C C C C C	Heterogeneity: Tau ²	= 0.11: Ch	i² = 73.2	22. df = 11	(P < 0.0	00001): l²	= 85%	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Test for overall effect	: Z = 1.12	(P = 0.2	26)	,	,,		0.01 0.1 1 10 100
early RRTRisk RatioRisk RatioStudy or SubgroupEventsTotalEventsTotalWeightM-H. Random, 95% ClM-H. Random, 95% ClBarbar201811124610224212.6%1.07 [0.87, 1.31]Image: Colspan="6">M-H. Random, 95% ClGaudry 2021521376314111.6%0.85 [0.64, 1.13]Image: Colspan="6">Total WeightGaudry201612931113430812.8%0.90 [0.64, 1.27]Jun2014391094411110.8%0.90 [0.64, 1.27]Lumlertgul20183658356011.4%1.06 [0.79, 1.43]Sean M 20205381465523146213.5%1.03 [0.93, 1.13]Tukaram E201310210201060.7%212.96 [13.41, 3382.83]Vaara201448480520.7%104.92 [6.65, 1655.79]Wald201590900441.15 [0.67, 1.99]Zarbock2016341124811910.5%0.75 [0.53, 1.07]Total (95% Cl)27282695100.0%1.08 [0.85, 1.36]Total events1204971Heterogeneity: Tau ² = 0.61 (P = 0.54)971Heterogeneity: Tau ² = 0.61 (P = 0.54)100	С							
Study or Subgroup Events Total Weight M-H. Random, 95% Cl M-H. Random, 95% Cl Barbar2018 111 246 102 242 12.6% 1.07 [0.87, 1.31] Gaudry 2021 52 137 63 141 11.6% 0.85 [0.64, 1.13] Gaudry 2016 129 311 134 308 12.8% 0.95 [0.79, 1.15] jun2014 39 109 44 111 10.6% 0.90 [0.64, 1.27] Lumlertgul2018 36 58 35 60 11.4% 1.06 [0.79, 1.43] Sean M 2020 538 1465 523 1462 13.5% 1.03 [0.93, 1.13] Tukaram E2013 102 102 0 106 0.7% 212.96 [13.41, 3382.83] Vaara2014 48 48 0 52 0.7% 104.92 [6.65, 1655.79] Wald2015 90 90 0 44 0.7% 89.51 [5.69, 1409.10] XIA 2019 15 30 13 30 8.0%		early F	RT	delayed	RRT		Risk Ratio	Risk Ratio
Barbar201811124610224212.6%1.07 [0.87, 1.31]Gaudry 2021521376314111.6%0.85 [0.64, 1.13]Gaudry 201612931113430812.8%0.95 [0.79, 1.15]jun2014391094411110.8%0.90 [0.64, 1.27]Lumlertgul20183658356011.4%1.06 [0.79, 1.43]Sean M 20205381465523146213.5%1.03 [0.93, 1.13]Srisawat201710209206.7%1.11 [0.58, 2.14]Tukaram E201310210201060.7%212.96 [13.41, 3382.83]Vaara201448480520.7%104.92 [6.65, 1655.79]Wald201590900440.7%89.51 [5.69, 1409.10]XIA 2019153013308.0%1.15 [0.67, 1.99]Zarbock2016341124811910.5%0.75 [0.53, 1.07]Total (95% CI)27282695100.0%1.08 [0.85, 1.36]Total events1204971971Heterogeneity: Tau ² = 0.11; Chi ² = 69.61, df = 11 (P < 0.00001); l ² = 84%0.010.1100.010.110100acriv PRTdelayed PRT	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
Gaudry 2021 52 137 63 141 11.6% 0.85 [0.64, 1.13] Gaudry2016 129 311 134 308 12.8% 0.95 [0.79, 1.15] jun2014 39 109 44 111 10.8% 0.90 [0.64, 1.27] Lumlertgul2018 36 58 35 60 11.4% 1.06 [0.79, 1.43] Sean M 2020 538 1465 523 1462 13.5% 1.03 [0.93, 1.13] Srisawat2017 10 20 9 20 6.7% 1.11 [0.58, 2.14] Tukaram E2013 102 102 0 106 0.7% 212.96 [13.41, 3382.83] Vaara2014 48 48 0 52 0.7% 104.92 [6.65, 1655.79] Wald2015 90 90 0 44 0.7% 89.51 [5.69, 1409.10] XIA 2019 15 30 13 30 8.0% 1.15 [0.67, 1.99] 1.08 0.01 0.1 10 Total (95% Cl) 2728 2	Barbar2018	111	246	102	242	12.6%	1.07 [0.87, 1.31]	
Gaudry2016 129 311 134 308 12.8% 0.95 [0.79, 1.15] jun2014 39 109 44 111 10.8% 0.90 [0.64, 1.27] Lumlertgul2018 36 58 35 60 11.4% 1.06 [0.79, 1.43] Sean M 2020 538 1465 523 1462 13.5% 1.03 [0.93, 1.13] Srisawat2017 10 20 9 20 6.7% 1.11 [0.58, 2.14] Tukaram E2013 102 102 0 106 0.7% 212.96 [13.41, 3382.83] Vaara2014 48 48 0 52 0.7% 104.92 [6.65, 1655.79] Wald2015 90 90 0 44 0.7% 89.51 [5.69, 1409.10] XIA 2019 15 30 13 30 8.0% 1.15 [0.67, 1.99] Zarbock2016 34 112 48 119 10.5% 0.75 [0.53, 1.07] Heterogeneity: Tau ² = 0.11; Chi ² = 69.61, df = 11 (P < 0.00001); l ² = 84% 0.01 0.1 10 100 carly PBT delayed PBT delayed PBT 100	Gaudry 2021	52	137	63	141	11.6%	0.85 [0.64, 1.13]	Ţ
jun2014 39 109 44 111 10.8% 0.90 [0.64, 1.27] Lumlertgul2018 36 58 35 60 11.4% 1.06 [0.79, 1.43] Sean M 2020 538 1465 523 1462 13.5% 1.03 [0.93, 1.13] Srisawat2017 10 20 9 20 6.7% 1.11 [0.58, 2.14] Tukaram E2013 102 102 0 106 0.7% 212.96 [13.41, 3382.83] Vaara2014 48 48 0 52 0.7% 104.92 [6.65, 1655.79] Wald2015 90 90 0 44 0.7% 89.51 [5.69, 1409.10] XIA 2019 15 30 13 30 8.0% 1.15 [0.67, 1.99] Zarbock2016 34 112 48 119 10.5% 0.75 [0.53, 1.07] Total (95% Cl) 2728 2695 100.0% 1.08 [0.85, 1.36] Total events 1204 971 Heterogeneity: Tau ² = 0.11; Chi ² = 69.61, df = 11 (P < 0.00001); l ² = 84% Test for overall effect: Z = 0.61 (P = 0.54)	Gaudry2016	129	311	134	308	12.8%	0.95 [0.79, 1.15]	T
Lumlertgul2018 36 58 35 60 11.4% 1.06 [0.79, 1.43] Sean M 2020 538 1465 523 1462 13.5% 1.03 [0.93, 1.13] Srisawat2017 10 20 9 20 6.7% 1.11 [0.58, 2.14] Tukaram E2013 102 102 0 106 0.7% 212.96 [13.41, 3382.83] Vaara2014 48 48 0 52 0.7% 104.92 [6.65, 1655.79] Wald2015 90 90 0 44 0.7% 89.51 [5.69, 1409.10] XIA 2019 15 30 13 30 8.0% 1.15 [0.67, 1.99] Zarbock2016 34 112 48 119 10.5% 0.75 [0.53, 1.07] Total (95% Cl) 2728 2695 100.0% 1.08 [0.85, 1.36] Total events 1204 971 Heterogeneity: Tau ² = 0.11; Chi ² = 69.61, df = 11 (P < 0.00001); l ² = 84% Test for overall effect: $Z = 0.61$ (P = 0.54)	jun2014	39	109	44	111	10.8%	0.90 [0.64, 1.27]	Ţ
Sean M 2020 538 1465 523 1462 13.5% 1.03 [0.93, 1.13] Srisawat2017 10 20 9 20 6.7% 1.11 [0.58, 2.14] Tukaram E2013 102 102 0 106 0.7% 212.96 [13.41, 3382.83] Vaara2014 48 48 0 52 0.7% 104.92 [6.65, 1655.79] Wald2015 90 90 0 44 0.7% 89.51 [5.69, 1409.10] XIA 2019 15 30 13 30 8.0% 1.15 [0.67, 1.99] Zarbock2016 34 112 48 119 10.5% 0.75 [0.53, 1.07] Total (95% Cl) 2728 2695 100.0% 1.08 [0.85, 1.36] Total events 1204 971 Heterogeneity: Tau ² = 0.11; Chi ² = 69.61, df = 11 (P < 0.00001); l ² = 84% 0.01 0.1 100 oright product is for overall effect: Z = 0.61 (P = 0.54) 100 acriv PRT delayed PRT	Lumlertgul2018	36	58	35	60	11.4%	1.06 [0.79, 1.43]	Т
Srisawat2017 10 20 9 20 6.7% 1.11 [0.58, 2.14] Tukaram E2013 102 102 0 106 0.7% 212.96 [13.41, 3382.83] Vaara2014 48 48 0 52 0.7% 104.92 [6.65, 1655.79] Wald2015 90 90 0 44 0.7% 89.51 [5.69, 1409.10] XIA 2019 15 30 13 30 8.0% 1.15 [0.67, 1.99] Zarbock2016 34 112 48 119 10.5% 0.75 [0.53, 1.07] Total (95% CI) 2728 2695 100.0% 1.08 [0.85, 1.36] Total events 1204 971 Heterogeneity: Tau ² = 0.11; Chi ² = 69.61, df = 11 (P < 0.00001); l ² = 84% 0.01 0.1 100 oright for overall effect: Z = 0.61 (P = 0.54) 90.00001); l ² = 84% 90.01 0.1 100	Sean M 2020	538	1465	523	1462	13.5%	1.03 [0.93, 1.13]	
Tukaram E2013 102 102 0 106 0.7% 212.96 [13.41, 3382.83] Vaara2014 48 48 0 52 0.7% 104.92 [6.65, 1655.79] Wald2015 90 90 0 44 0.7% 89.51 [5.69, 1409.10] XIA 2019 15 30 13 30 8.0% 1.15 [0.67, 1.99] Zarbock2016 34 112 48 119 10.5% 0.75 [0.53, 1.07] Total (95% CI) 2728 2695 100.0% 1.08 [0.85, 1.36] Total events 1204 971 Heterogeneity: Tau ² = 0.11; Chi ² = 69.61, df = 11 (P < 0.00001); l ² = 84% 0.01 0.1 1 10 100 Cost for overall effect: Z = 0.61 (P = 0.54) 90.00001; l ² = 84% 90.00001; l ² = 84% 90.01 0.1 1 100	Srisawat2017	10	20	9	20	6.7%	1.11 [0.58, 2.14]	
Vaara2014 48 48 0 52 0.7% 104.92 [6.65, 1655.79] Wald2015 90 90 0 44 0.7% 89.51 [5.69, 1409.10] XIA 2019 15 30 13 30 8.0% 1.15 [0.67, 1.99] Zarbock2016 34 112 48 119 10.5% 0.75 [0.53, 1.07] Total (95% CI) 2728 2695 100.0% 1.08 [0.85, 1.36] Total events 1204 971 Heterogeneity: Tau ² = 0.11; Chi ² = 69.61, df = 11 (P < 0.00001); l ² = 84% 0.01 0.1 1 10 100 Test for overall effect: Z = 0.61 (P = 0.54) 0.54 0.01 0.1 1 10 100	Tukaram E2013	102	102	0	106	0.7%	212.96 [13.41, 3382.83]	
Wald2015 90 90 0 44 0.7% 89.51 [5.69, 1409.10] XIA 2019 15 30 13 30 8.0% 1.15 [0.67, 1.99] Zarbock2016 34 112 48 119 10.5% 0.75 [0.53, 1.07] Total (95% CI) 2728 2695 100.0% 1.08 [0.85, 1.36] Total events 1204 971 Heterogeneity: Tau ² = 0.11; Chi ² = 69.61, df = 11 (P < 0.00001); l ² = 84% 0.01 0.1 1 10 100 Test for overall effect: Z = 0.61 (P = 0.54)	Vaara2014	48	48	0	52	0.7%	104.92 [6.65, 1655.79]	
XIA 2019 15 30 13 30 8.0% 1.15 [0.67, 1.99] Zarbock2016 34 112 48 119 10.5% 0.75 [0.53, 1.07] Total (95% Cl) 2728 2695 100.0% 1.08 [0.85, 1.36] Total events 1204 971 Heterogeneity: Tau ² = 0.11; Chi ² = 69.61, df = 11 (P < 0.00001); l ² = 84% 0.01 0.1 1 10 100 Test for overall effect: Z = 0.61 (P = 0.54) early PPT delayed PPT	Wald2015	90	90	0	44	0.7%	89.51 [5.69, 1409.10]	
Zarbock2016 34 112 48 119 10.5% 0.75 $[0.53, 1.07]$ Total (95% CI) 2728 2695 100.0% 1.08 $[0.85, 1.36]$ Total events 1204 971 Heterogeneity: Tau ² = 0.11; Chi ² = 69.61, df = 11 (P < 0.00001); I ² = 84% 0.01 0.1 1 10 100 Test for overall effect: Z = 0.61 (P = 0.54) early PET delayed PET	XIA 2019	15	30	13	30	8.0%	1.15 [0.67, 1.99]	
Total (95% CI) 2728 2695 100.0% 1.08 [0.85, 1.36] Total events 1204 971 Heterogeneity: Tau ² = 0.11; Chi ² = 69.61, df = 11 (P < 0.00001); I ² = 84% 0.01 0.1 1 10 100 Test for overall effect: Z = 0.61 (P = 0.54) 0.01 0.1 1 10 100	Zarbock2016	34	112	48	119	10.5%	0.75 [0.53, 1.07]	-
Total events 1204 971 Heterogeneity: Tau ² = 0.11; Chi ² = 69.61, df = 11 (P < 0.00001); l ² = 84% Image: Heterogeneity = 0.01 Test for overall effect: Z = 0.61 (P = 0.54) 0.01 0.1 1 10 100	Total (95% CI)		2728		2695	100.0%	1.08 [0.85, 1.36]	
Heterogeneity: Tau ² = 0.11; Chi ² = 69.61, df = 11 (P < 0.00001); l ² = 84% Test for overall effect: Z = 0.61 (P = 0.54)	Total events	1204		971				
Test for overall effect: Z = 0.61 (P = 0.54)	Heterogeneity: Tau ² =	0.11: Chi ²	= 69.6	1, df = 11	(P < 0.0	0001): l² =	= 84%	
	Test for overall effect:	Z = 0.61 (P = 0.54	4)				0.01 0.1 1 10 100 early RRT delayed RRT

FIGURE 5 | Forest plot for all-cause mortality at day 28 of sensitivity analysis by removing individual trials at a time with non-low bias in each domain (A); best-worst-case scenario random-effects meta-analysis for the rate of all-cause mortality at day 28 (B); and worst-best-case scenario random-effects meta-analysis for the rate of all-cause mortality at day 28 (C).

"worst-best-case" scenario to assess the possible impact of missing data on the robustness of results and performed subgroup analyses to explore eventual heterogeneity. (4) We also conducted TSA to ascertain the trend of uncertain outcomes and provide "futility boundaries" that can draw invalid conclusions as soon as possible, preventing researchers from spending a lot of resources on unneeded research.

There were several limitations in our analysis. First, the heterogeneity of studies, particularly the definition of eRRT and dRRT was quite various and might affect the accuracy of our results. Second, there is an inability to assess all possible causes of heterogeneity, the decision regarding the optimal timing of RRT lack of objective basis. Third, the total adverse events and other specific adverse events showed contradictory results, the inconsistency possibly due to the inclusion of different studies for analysis.

CONCLUSION

Early RRT strategy provided no significant survival benefit for ill patients with AKI compared with the dRRT strategy, and TSA indicated that no more studies were needed to confirm it.

DATA AVAILABILITY STATEMENT

All data generated or analyzed during this study are included in this published article (and its **Supplementary Material**), further inquiries can be directed to the corresponding author

AUTHOR CONTRIBUTIONS

CX contributed to the study concept and design, drafting of the manuscript. CX, JX, and YC contributed to the acquisition, analysis, and interpretation of data, and statistical analysis. QL, WL, TH, SL, and DG helped in data arrangement. FS contributed to study concept,

REFERENCES

- Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. *Intensive Care Med.* (2015) 41:1411– 23. doi: 10.1007/s00134-015-3934-7
- Kellum JA, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). *Critical Care.* (2013) 17:204. doi: 10.1186/cc11454
- Shiao C-C, Huang T-M, Spapen HD, Honore PM, Wu V-C. Optimal timing of renal replacement therapy initiation in acute kidney injury: the elephant felt by the blindmen? *Critical Care.* (2017) 21:146. doi: 10.1186/s13054-017-1713-2
- Zarbock A, Mehta RL. Timing of kidney replacement therapy in acute kidney injury. *Clin J Am Soc Nephrol.* (2019) 14:147–9. doi: 10.2215/CJN.08810718
- Wald R, Bagshaw SM. The timing of renal replacement therapy initiation in acute kidney injury. *Semin Nephrol.* (2016) 36:78– 84. doi: 10.1016/j.semnephrol.2016.01.009
- Zarbock A, Kellum JA, Schmidt C, Van Aken H, Wempe C, Pavenstädt H, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically Ill patients with acute kidney injury: the ELAIN randomized clinical trial. *JAMA*. (2016) 315:2190–9. doi: 10.1001/jama.2016.5828

supervision, and organizing the final manuscript. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS

We thank Ph.D. Wei Qiang, the librarian of Guizhou Medical University for her help with the search strategies. We thank the associate editor and the reviewers for their useful feedback to improve this paper.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed. 2022.820624/full#supplementary-material

Supplementary Figure S1 | Forest plot for all-cause mortality at day 60. The size of each square represents the proportion of information provided by each study (A); forest plot for all-cause mortality at day 90 (B); forest plot for all-cause mortality in an intensive care unit (ICU) (C); and forest plot for all-cause mortality in a hospital (D).

Supplementary Figure S2 | Trial sequential analysis (TSA) for all-cause mortality at day 60 (A); TSA for all-cause mortality at day 90 (B); TSA for all-cause mortality in an ICU (C); and TSA for all-cause mortality in a hospital (D).

Supplementary Figure S3 | Forest plot for the rate of renal replacement therapy (RRT) during the study period (A) and TSA for the rate of RRT during the study period (B).

Supplementary Figure S4 | Forest plot for ventilator-free days at day 28 (A) and forest plot for vasoactive agent-free days at day 28 (B).

Supplementary Figure S5 | Forest plot for the rate of RRT dependence at day 28 (A) and TSA for the rate of RRT dependence at day 28 (B).

Supplementary Figure S6 | Forest plot for the length of stay (LOS) of survivors in ICU (A) and forest plot for the LOS of the survivors in a hospital (B).

Supplementary Figure S7 | Forest plot for the rate of total adverse events (A); TSA for the rate of total adverse events (B); forest plot for the rate of bleeding (C); forest plot for the rate of arrhythmia (D); and forest plot for the rate of hypotension (E).

- Vanmassenhove J, Vanholder R, Van Biesen W, Lameire N. Haste makes waste-Should current guideline recommendations for initiation of renal replacement therapy for acute kidney injury be changed? *Semin Dial.* (2018) 31:204–8. doi: 10.1111/sdi.12693
- Lin WT, Lai CC, Chang SP, Wang JJ. Effects of early dialysis on the outcomes of critically ill patients with acute kidney injury: a systematic review and meta-analysis of randomized controlled trials. *Sci Rep.* (2019) 9:18283. doi: 10.1038/s41598-019-54777-9
- Komaru Y, Doi K. Early or delayed initiation of renal replacement therapy for critically ill patients-do we know the right time? J Thoracic Dis. (2016) 8:E1006–E9. doi: 10.21037/jtd.2016.08.22
- Karakala N, Tolwani AJ. Timing of renal replacement therapy for acute kidney injury. J Intensive Care Med. (2019) 34:94– 103. doi: 10.1177/0885066618774257
- Schiffl H. Timing of renal replacement therapy in acute kidney injury: shedding new light on an old controversy. *Indian J Crit Care Med.* (2018) 22:730–2. doi: 10.4103/ijccm.IJCCM_295_18
- Barbar SD, Clere-Jehl R, Bourredjem A, Hernu R, Montini F, Bruyère R, et al. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. *N Engl J Med.* (2018) 379:1431–42. doi: 10.1056/NEJMoa18 03213

- Lumlertgul N, Peerapornratana S, Trakarnvanich T, Pongsittisak W, Surasit K, Chuasuwan A, et al. Early versus standard initiation of renal replacement therapy in furosemide stress test non-responsive acute kidney injury patients (the FST trial). *Critical Care.* (2018) 22:101. doi: 10.1186/s13054-018-2021-1
- Yang XM, Tu GW, Gao J, Wang CS, Zhu DM, Shen B, et al. A comparison of preemptive versus standard renal replacement therapy for acute kidney injury after cardiac surgery. J Surg Res. (2016) 204:205– 12. doi: 10.1016/j.jss.2016.04.073
- Bagshaw SM, Wald R, Adhikari NKJ, Bellomo R, da Costa BR, Dreyfuss D, et al. Timing of initiation of renal-replacement therapy in acute kidney injury. *N Engl J Med.* (2020) 383:240–51. doi: 10.1056/NEJMoa2000741
- Stéphane Gaudry DH, Martin-Lefevre L, Lebbah S, Louis G. Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial. *Lancet.* (2021) 397:1293–300. doi: 10.1016/S0140-6736(21)00350-0
- Ioannidis JPA, Lau J. Evolution of treatment effects over time: Empirical insight from recursive cumulative metaanalyses. *Proc Natl Acad Sci USA*. (2001) 98:831–6. doi: 10.1073/pnas.98.3.831
- Zhang S, Tang Q, Wu W, Yuan B, Lu C, Xia Y, et al. Association between DAZL polymorphisms and susceptibility to male infertility: systematic review with meta-analysis and trial sequential analysis. *Sci Rep.* (2014) 4:4642. doi: 10.1038/srep04642
- Wetterslev J, Jakobsen JC, Gluud C. Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Med Res Methodol. (2017) 17:39. doi: 10.1186/s12874-017-0315-7
- Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. *JAMA*. (2015) 313:1657–65. doi: 10.1001/jama.2015.3656
- 21. Section 2: AKI definition. *Kidney Int Suppl (2011).* (2012) 2:19–36. doi: 10.1038/kisup.2011.32
- Higgins JPT TJ, Chandler J. Cochrane Handbook for Systematic Reviews of Interventions version 6.1. Cochrane (2020). Available from cochrane.org/handbook. Cochrane Database of Systematic Reviews. doi: 10.1002/9781119536604 (updated September 2020).
- Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB
 a revised tool for assessing risk of bias in randomised trials. *BMJ*. (2019) 366:l4898. doi: 10.1136/bmj.l4898
- Gordon H. Guyatt ADo, Gunn e Vist, Regina Kunz. GrADE: an emerging consensus on rating quality of evidence and strength of recommendations. *Br Med J.* (2008) 336:924–6. doi: 10.1136/bmj.39489.470 347.AD
- Jakobsen JC WJ, Winkel P. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. *BMC Med Res Methodol.* (2014) 14:120. doi: 10.1186/1471-2288-14-120
- 26. Bjelakovic G, Nikolova D, Gluud C. Meta-regression analyses, metaanalyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm? *PLoS ONE.* (2013) 8:e74558. doi: 10.1371/journal.pone.007 4558
- 27. Copenhagen Trial Unit, User manual for Trial Sequential Analysis.0.9. Beta. Copenhagen: Copenhagen Trial Unit (2017).
- Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol. (2008) 61:763–9. doi: 10.1016/j.jclinepi.2007.10.007
- Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? *Int J Epidemiol.* (2009) 38:276–86. doi: 10.1093/ije/dyn179
- Gaudry S, Hajage D, Schortgen F, Martin-Lefevre L, Pons B, Boulet E, et al. Initiation strategies for renal-replacement therapy in the intensive care unit. N Engl J Med. (2016) 375:122–33. doi: 10.1056/NEJMoa16 03017

- Jun M, Bellomo R, Cass A, Gallagher M, Lo S, Lee J. Timing of renal replacement therapy and patient outcomes in the randomized evaluation of normal versus augmented level of replacement therapy study. *Crit Care Med.* (2014) 42:1756–65. doi: 10.1097/CCM.0000000000 00343
- 32. Vaara ST, Reinikainen M, Wald R, Bagshaw SM, Pettilä V. Timing of RRT based on the presence of conventional indications. *Clin J Am Soc Nephrol.* (2014) 9:1577–85. doi: 10.2215/CJN.126 91213
- 33. Wald R, Adhikari NK, Smith OM, Weir MA, Pope K, Comparison of standard and accelerated Cohen A, et al. initiation of renal replacement therapy in acute kidnev injury. Kidney Int. (2015) 88:897–904. doi: 10.1038/ki.20 15,184
- 34. Srisawata N, Laoveeravat P, Limphunudom P, Lumlertgul N. The effect of early renal replacement therapy guided by plasma neutrophil gelatinase associated lipocalin on outcome of acute kidney injury: a feasibility study. *J Critical Care.* (2018) 43:36–41. doi: 10.1016/j.jcrc.2017. 08.029
- 35. Jamale TE, Hase NK, Kulkarni M, Pradeep KJ, Keskar V, Jawale S, et al. Earlier-start versus usual-start dialysis in patients with community-acquired acute kidney injury: a randomized controlled trial. Am J Kidney Dis. (2013) 62:1116–21. doi: 10.1053/j.ajkd.2013. 06.012
- 36. Yan-mei XIA H-pS, Wei-dong WU, Xiu-zhe WANG. Effect of urinary NGAL on the timing of renal replacement therapy in patients with acute renal injury associated with sepsis. *Med J Chin People's Liber Army*. (2019) 44: 605–10.
- Bagshaw SM, Wald R. Strategies for the optimal timing to start renal replacement therapy in critically ill patients with acute kidney injury. *Kidney Int.* (2017) 91:1022–32. doi: 10.1016/j.kint.2016. 09.053
- Kidney Disease Improving Global Outcome. KDIGO Clinical Practice Guideline for Acute Kidney Injury. (2012) Available at: http://kdigo.org/home/ guidelines/acute-kidney-injury/~
- Prowle JR, Davenport A. Does early-start renal replacement therapy improve outcomes for patients with acute kidney injury? *Kidney Int.* (2015) 88:670–3. doi: 10.1038/ki.20 15.225
- Pasin L, Boraso S, Tiberio I. Early initiation of renal replacement therapy in critically ill patients: a meta-analysis of randomized clinical trials. *BMC Anesthesiol.* (2019) 19:62. doi: 10.1186/s12871-019-0733-7
- Andonovic M, Shemilt R, Sim M, Traynor JP, Shaw M, Mark PB, et al. Timing of renal replacement therapy for patients with acute kidney injury: A systematic review and meta-analysis. *J Intens Care Soc.* (2021) 22:67– 77. doi: 10.1177/1751143720901688
- Fayad AII, Buamscha DG, Ciapponi A. Timing of renal replacement therapy initiation for acute kidney injury. *Cochr Database Syst Rev.* (2018) 12:CD010612. doi: 10.1002/14651858.CD010612.pub2
- 43. Xiaoming Li CL, Mao Z, Li Q, Zhou F. Timing of renal replacement therapy initiation for acute kidney injury in critically ill patients: a systematic review of randomized clinical trials with meta-analysis and trial sequential analysis. *Critical Care.* (2 021) 25.
- Zou H, Hong Q, Xu G. Early versus late initiation of renal replacement therapy impacts mortality in patients with acute kidney injury post cardiac surgery: a meta-analysis. *Critical Care.* (2017) 21:150. doi: 10.1186/s13054-017-1707-0
- 45. Wang C, Lv LS, Huang H, Guan J, Ye Z, Li S, et al. Initiation time of renal replacement therapy on patients with acute kidney injury: a systematic review and meta-analysis of 8179 participants. *Nephrology.* (2017) 22:7–18. doi: 10.1111/nep. 12890
- 46. Borm GF, Donders AR. Updating meta-analyses leads to larger type I errors than publication bias. J Clin

Epidemiol. (2009) 62:825–30 e10. doi: 10.1016/j.jclinepi.2008. 08.010

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Xiao, Xiao, Cheng, Li, Li, He, Li, Gao and Shen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.